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Abstract
Hyperbilirubinemia is the most common clinical diagnosis during neona-
tal life. The neonatal jaundice may be physiological without any
clinical consequence, or can lead to an acute form of bilirubin en-
cephalopathy with minimal neurological damage, or to more severe
and dangerous condition called kernicterus (permanent neurological
sequelae).
The Gunn rat is one of the models in which bilirubin encephalopathy
was studied. It was shown that jaundiced newborn animals display
an hepatic compensatory mechanism for the incapacity to eliminate
bilirubin (Ugt1A1 mutant enzyme) by upregulation of cyotochrome
P450 enzymes (Cyp) 1A1 and 1A2 compared with their not jaun-
diced littermates. In addition, their expression in brain was selec-
tively induced (cortex higher and early vs. cerebellum lower and late
induction) by sudden increase of bilirubin content.
Cyotochrome P450 enzymes are the main enzymes involved in the
detoxification of drug and endogenous compounds. In liver their role
in bilirubin oxidation has been deeply demonstrated. In brain, there
are many works that analyzed Cyps expression and induction, but
their role in bilirubin oxidation has never been evaluated till now.
This thesis focused in; 1) analyze the inducibility of Cyps enzymes, by
a known inducer, βNF in cortex and cerebellum astrocytes; 2) Select
the optimal conditions to induce specifically each of them; 3) analyze
their activity and 4) evaluate their capacity to oxidize bilirubin; 5)
Last but not least, assess the protective effect of Cyps induction by
challenging the cells with high concentrations of bilirubin.
We demonstrated that astrocytes Cyps were inducible (both mRNA
and activity) by βNF and this induction varies depending on the brain
region and among the Cyps. To explain the differences we hypoth-
esized the presence of: i) a different protein isoforms (discarded for
Cyp1A1) ii) different maturation stage of astrocytes in the two brain
regions (P2 rats: Cll is less developed than Cx), iii) differential regu-
latory mechanisms.
Our work showed that in Cx astrocytes Cyp1A1 induction (mRNA
and activity) was an early event (6h), requiring low concentration of
the drug, making this approach theoretically possible in vivo. On the
other hand, to reach the higher levels of Cyp1A1 (mRNA and activ-
ity) in Cll we needed 24h. In both cases Cyp1A1 was able to oxidize
bilirubin producing an increase in viability only after TCB addition.
The Cyp1A2 was the major catalyst of bilirubin degradation (with-
out the need of TCB), but its modulation was more difficult to be
achieved. In addition, while Cyp1A2 modulation increased bilirubin
oxidation in cortex (also reflected in an increment in viability), in
cerebellum we noticed a slight reduction in bilirubin clearance (no
improvements in viability). All this data could lead to the basis of
the cerebellum susceptibility to UCB. The observation that the TCB
addition in Cyp1A1 astrocytes increases bilirubin oxidation and via-
bility suggest the possibility to induce Cll resistance toward bilirubin
neurotoxicity by Cyps modulation and uncoupling.
Riassunto
Una delle condizioni neonatali piu` comuni e` l’ittero. Esso rappresenta
l’aumento fisiologico della bilirubina nel sangue e tessuti. Tuttavia
esso puo` divenire una condizione patologica (encefalopatia da biliru-
bina), caratterizzata da un danno neurologico minimo, o condurre a
una condizione severa e pericolosa per il neonato chiamata kernit-
tero (danni permanenti), in caso di una esposizione prolungata ad alti
livelli del pigmento. Attualmente, la patologia da iperbilirubinemia
rappresenta la principale causa di riammissione in ospedale nel primo
mese di vita.
Per il danno neurologico da bilirubina esiste un modello animale,
il ratto Gunn, che presenta la stessa mutazione genica dei pazienti
Crigler-Najjar I. Come nella condizione umana, esso manca della
uridin di fosfo glucuronisil tranferasi 1a1 (Ugt1A1), enzima epatico
deputato alla coniugazione della bilirubina. Tuttavia l’animale ri-
esce a compensare la mancanza mantenendo bassi i livelli serici di
bilirubina, grazie ad una incrementata attivita` delle citocromo P450
mono-ossigenasi epatiche (Cyps, Cyp1A1 and Cyp1A2). Tali enzimi
riducono la concentrazione del pigmento attraverso la sua ossidazione.
E` stato supposto che questo meccanismo possa essere alla base anche
della capacita` di specifiche aree del cervello (cortex e collicoli superiori,
vs. i danneggiati cervelletto, ippocampo e collicoli inferiori) di ridurre
la concentrazione del pigmento, limitando/impedendo il danno neu-
rologico associato. Sebbene il loro ruolo, i meccanismi ed i prodotti
della loro attivita` di clearance della bilirubina siano stati ampiamente
dimostrati in fegato, in cervello non sono ancora disponibili evidenze
funzionali della loro capacita` di ossidare la bilirubina.
L’obiettivo di questa tesi e` stato di analizzare 1) la modulazione delle
Cyps cerebrali (brain Cyp: bCyp) utilizzando un noto induttore, βNF;
2) selezionare le condizione ottimali per una induzione selettiva di cias-
cuna bCyp; 3) allo scopo di valutare la loro attivita` (EROD/MROD);
4) e la capacita` specifica di ossidare bilirubina; 5) conferendo pro-
tezione (aumento vitalita`) alle culture primarie di astrociti (da cortex
e cervelletto) esposte a dosi tossiche di bilirubina.
Questo studio ha dimostrato la inducibilita` delle bCyps (mRNA e
attivita`) tramite βNF. Abbiamo evidenziato una modulazione dipen-
dente della regione cerebrale da cui sono state prodotte le cellule, in
aggiunta ad un comportamento differenziale delle Cyps tra loro. Pos-
sibili spiegazioni possono essere: i) la presenza di diverse isoforme tra
le regioni (ipotesi scartata in seguito ad analisi tramite western blot);
ii) diversa presenza delle vie di segnalazione alla base dei meccanismi
di modulazione, o, iii) una diversa risposta dovuta al diverso stadio
sviluppo degli astrociti preparati dalle due regioni (ratti P2: il Cll e`
meno sviluppato del Cx).
Inoltre, abbiamo documentato una precoce (6h) inducibilita` della
Cyp1A1 nei astrociti dal Cx, che inoltre necessita` di minori concen-
trazioni del principio. Tali caratteristiche suggeriscono che la Cyp1A1
sia piu` facilmente modulabile in vivo. Tuttavia, per ottenere una
buona modulazione nel cervelletto (regione piu` sensibile al danno),
bisogna mantenere la concentrazione dell’ induttore per un tempo
lungo (24h). In entrambe le regioni, un incremento significativo della
capacita` di ossidare bilirubina, migliorando la vitalita` delle cellule,
e` stato ottenuto solo dopo il co-trattamento con TCB (disaccoppia-
mento). La Cyp1A2 e` stata significativamente modulata solo negli
astrociti da Cx (24h), in cui abbiamo evidenziato un chiara capacita`
dell’enzima di ossidare la bilirubina e migliorare la vitalita` in assenza
di TCB. I risultati ottenuti permettono di comprendere la suscettibilita`
differenziale (tra regioni del cervello) tipica di questa patologia. La
capacita` di indurre Cyp1A1 e renderli pronti a ossidare la bilirubina
nei astrociti da Cll (regione piu` danneggiata) e Cyp1A1/Cyp1A2 in
Cx e oltre migliorando la viabilita` di questi suggeriscono la possibilita`
di conferire resistenza a la tossicita` da bilirubina.
This study was supported by a fellowship from the Italian Ministry of Foreign
Affairs (MAE) in Rome, Italy. In particular, I would like to thank Dr. Paola
Ranocchia.
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1Introduction
1.1 Bilirubin
Bilirubin (BR) consists of an open chain of four pyrrole-like rings (tetrapyr-
role) and is the end product of catabolism of the heme group present in hemoglobin,
myoglobin and some cellular enzymes.
1.1.1 Bilirubin metabolism
80% of the bilirubin produced in human body derives from heme catabolism
liberated from senescent red cells, 15-20% from turnover of myoglobin, cytochromes
and other hemoproteins, and finally less than 3% from destruction of immature
red blood cells. This breakdown generates between 250 and 400mg of the pigment
daily in humans (85, 101).
The heme group is broken by the heme oxygenase (HO-1) enzyme. The reac-
tion to proceeds requires nicotinamide-adenine dinucleotide phosphate (NADPH)
as reducing agent and three molecules of oxygen. This reaction require a com-
plex series of oxidations and reductions, ultimately breaking the methane bridge
in heme releasing carbon monoxide (CO) and ferrous iron (Fe+2) and biliverdin
(128, 136). The next step is the conversion of biliverdin to bilirubin by the cy-
tosolic biliverdin reductase enzyme (BVR), in the presence of NADPH (Fig. 1.1).
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The bilirubin formed in the various tissues efflux into blood serum (138). As it
is water insoluble, unconjugated bilirubin (UCB) binds tightly to albumin (but
reversible) and is transported to the liver where is removed from the plasma. The
binding to albumin protects against toxic effects of bilirubin.
Figure 1.1: Heme degradation.
Microsomal heme oxygenase catalyzes the rate limiting step in heme metabolism. (Adapted from Ryter et.al
(115))
The hepatic parenchyma absorbs the BR from the serum, the excact mecha-
nism of UCB uptake is unknown; however, passive diffusion seems to be combined
with intracellular carrier proteins such as ligandin (glutathione-S-transferase,
OATP) facilitating the intracellular hepatic transport of BR (44, 130, 148). In the
liver, UCB interacts mainly with several detoxifying enzymes such as glutathione-
S-transferases (GSTs) and UDP-glucuronosyltransferases (UGTs). Unconjugated
bilirubin is taken up by hepatocytes binds to cytosolic isoforms of GST (mainly
2
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alpha, named ligandin), which maintains the gradient of free UCB, facilitates the
UCB transfers to the endoplasmic reticulum, limiting the efflux from the cell, and
protect hepatocites despite the high concentration that the pigment may reach
in this organ (44, 149).
The main pathway of bilirubin detoxication in the liver is the conjugation with
glucuronic acid (one or two molecules). It is catalyzed by the uridine diphospho-
glucuronate glucoronosyltransferase enzyme (UGT1A1) in the endoplasmic retic-
ulum forming mono and diglucuronides, knowns as conjugated bilirubin (CB)
(18, 57, 67). This pathway leads to the production of more water soluble metabo-
lites which are transported into the bile by ATP-dependent transporter identified
as the multidrug resistance-associated protein MRP2/cMOAT and, to a lesser
extent, also by ATP-binding cassette (ABC) efflux transporter ABCG2 (69, 130)
(Fig. 1.2).
Recent studies have shown that under physiologic conditions, a fraction of the
conjugated bilirubin in the liver is not excreted into bile but is transported back to
the blood. OATP1A/1B activity in a downstream hepatocyte allows an efficient
take back of this CB for final biliary excretion (62, 63, 138). The process is medi-
ated by sinusoidal transporters MRP3 (ABCC3) and organic anion-transporting
polypeptides OATP1B1 and OATP1B3. In addition, this OATP1B proteins me-
diate hepatic clearance of bilirubin conjugated in viceral organs and may be an
important alternative pathway in enterohepatic circulation (138).
In the colon, the glucuronide residues of CB are released by bacterial hydro-
lases and the pigment is oxidize to urobilinoids, mostly excreted by feces. A small
proportion of UCB is reabsorbed returning to the liver and secreted again to the
bile (106).
1.1.2 Total, direct and indirect bilirubin in blood
In blood, the total bilirubin (TBS) is formed by three principals forms: albu-
min bound unconjugated bilirubin (A-UCB), conjugated bilirubin (direct biliru-
bin, CB) and unbound unconjugated bilirubin (free bilirubin; Bf). The Bf repre-
sents less than 0.1% of the pigment in normal condition (6, 144).
3
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Figure 1.2: Hepatic metabolism of bilirubin.
Briefly, Bilirubin is transported to hepatocyes by facilitated diffusion and OATP1A/1B transporters. Within
the hepatocytes bilirubin binds to GSTs. Bilirubin is converted to mono or di-glucuronide by UGT1A1.
Finally, Conjugated bilirubin (CB) is actively transported into bile by MRP2 or ABCG2.
The measure of TBS is usually performed by the diazo method. Briefly,
bilirubin is coupled with diazotized sulphanilic acid in acidic medium to form
the pink colored azobilirubin. The intensity of the color produced is directly
proportional to total bilirubin (CB and the two form of UCB, A-UCB and Bf)
concentration present in the sample (35, 36).
1.1.3 The free bilirubin theory
Clinically, laboratory measurements of unbound circulating bilirubin is not
generally available and the B/A ratio is used to extrapolated it level. If the
amount of bilirubin does not exceed the albumin binding capacity (B/A ratio less
than 1) the maximal amount of UCB is bound to albumin (435µM; 25mg/dL;
(19)). If UCB concentration is higher than the binding capacity (B/A ratio more
than 1), the amount of Bf rises. In this conditions, the UCB (that is lipophilic)
can passively diffuse across the membranes and accumulates into the tissues (34,
102, 148). The proportion of free UCB depends not only to the presence of
albumin but also its binding affinity constants. In newborn, the albumin affinity
4
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constant for bilirubin (α-fetoprotein) is lower compared to adults (HSA) (102).
Moreover, some drugs or competitor substance, commonly used in neonates, can
modified the binding affinity(112). Considering the above statements, the Bf
measure by B/A ratio is an aproximative method.
1.1.4 Bilirubin in newborns
In utero, the excretory function of UCB is limited to the active transport
from the placenta to the maternal circulation (123). At birth, the newborn, now
without the placental protection, has to deal with an increase in catabolism of
red cell hemoglobin to UCB loading the liver. In addition, neonates lack of anaer-
obic ileo-colonic flora that convert UCB into urobilinogens, thus increasing the
enterohepatic circulation of UCB (32). Moreover, delayed maturation of hepatic
transport processes and glucuronidation ability results in significant retention of
UCB even in healthy babies (50, 102). All this lead to a plasma bilirubin peak
approximately 1 week of after birth and then return to normal. The average
full-term infant has a peak serum bilirubin concentration of 5 to 10 mg/dL (86 to
170 µM). After a month, the processes of uptake, storage, conjugation and biliary
secretion of bilirubin should be matured to near adult levels (≤1-2mg/dL) (50).
Neonatal physiological jaundice may be aggravated by a combination of: aug-
mented bilirubin production (e.g. haemolysis), increased enterohepatic circu-
lation of UCB, hereditary defects, prematurity or abnormal maturation of the
hepatic conjugation mechanism (68, 72, 86, 129). In addition, nowadays, early
discharge from hospital (before bilirubin peaks) could lead to brain damage (Fig.
1.3) (11, 93). If blood bilirubin concentrations is not properly supervised and
family lack of knowledge about bilirubin potential damage may turn out in high
bilirubin brain concentration and produce bilirubin induced neurologic dysfunc-
tion (BIND).
5
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Figure 1.3: Jaundice in newborn.
(taken from A.D.A.M. encyclopedia)
1.1.5 Disorders of Bilirubin metabolism
1.1.5.1 Disorders leading to unconjugated hyperbilirubinemia
Bilirubin encephalopathy
Bilirubin encephalopathy (bilirubin induced neurologic dysfunction; BIND)
occurs when the pigment rises and accumulates in the body and brain (UCB
surpass the blood brain barrier (BBB)) (128). This condition is caused by mod-
erated levels of hyperbilirubinemia (200-300µM; 11.7 mg/dL). In general, BIND
is a reversible event, particularly at the early stages. The spectrum of mani-
festations varies from acute bilirubin encephalopathy to chronic sequelae. Mild
stages present hypotonia, lethargy, poor sucking and abnormal brainstem audi-
tory evoked potentials (BAEPs). With more severe or prolonged jaundice hyper-
tonia, opisthotonus, a high-pitched cry, impairment of up gaze, fever and wors-
ening the BAEPs can be observed. Irreversible neurological signs may develop
principally when no treatment was promptly applied. They account for sub-
tle deficits, including delay in motor development, impaired cognitive function
and auditory dysfunction, to more severe motor auditory, and cognitive disorders
(65, 79, 102, 125).
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Several studies reported that there are some points of decrease in de IQ score
between high and low levels of bilirubin. Of course the cause-reltaion is debated
due to the influence others factors, like family, social, stress, educational (65).
Commonly, phototherapy is the preferred treatment, but when do not response
clinicians opt for the exchange transfusion and albumin infusion (54).
Kernicterus
The kernicterus nowadays is referred to the selective damage to globuls pal-
lidus, substantia nigra, subthalamic nucleus, brainstem auditory, vestibular and
oculomotor nuclei, hippocampus and cerebellum. Some abnormalities can be seen
in magnetic resonance imaging scans (MRI), presenting loss of neurons demyeli-
nation and gliosis. This is characteristic in infants that suffer the irreversible
sequelae of the acute bilirubin encephalopathy (ABE). The common sequelae
include abnormal motor control, movements and muscle tone; auditory abnor-
malities (that include auditory neuropathy/dys-synchrony (AN/AD)) which may
or not be accompanied by deafness; oculomotor impairments such upward gaze
abnormalities; and dysplasia of the enamel of deciduous teeth (65, 125).
Crigler-Najjar syndrome
The CriglerNajjar syndrome (CNS) was first described in 1952 by Crigler
and Najjar (24). Is a rare genetic disorder (one in a million neonates) that cause
by persistent unconjugated hyperbilirubinemia. The UGT1A genes alteration are
responsible for the disruption of the metabolic pathway, inherited in an autosomal
recessive manner.
Type I (CNS-I) is the most severe type, characterized by a complete loss of
bilirubin glucuronidation. They present mutations within the exons 2, 3 and 4 of
the UGT1A gene locus, affecting all transcripts (hepatic and extra hepatic) (131).
Serum bilirubin levels range from 15 to 50mg/dL and, if untreated with exchange
transfusions and daily phototherapy, may result in permanent neurological dam-
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age or even to death. Currently, as patients lack of response to phenobarbital
treatments, liver transplantation is the only definitive cure (116, 139).
In Type II (CNS-II), individuals have a partial function of the UGT1A (30%
of normal the activity)(17). Even though it is compatible with normal life span,
the absence of prompt suspicion and proper management can prove fatal not only
in the neonatal period but also in the adult life. The bilirubin levels are lower
compared to CNS-I (between 10-20mg/dL), and patients respond to phenobar-
bital that induce the residual UGT1A1. In animal model also the alternative
oxidative mechanism by the Cytochrome P450 enzymes (see section 1.3) is acti-
vated, reducing bilirubin levels. In some patients, phototherapy is also used in
conjunction with phenobarbital (84).
Gilbert Syndrome
The syndrome is characterized by a mild fluctuating hyperbilirubinemia occur-
ring in the absence of hemolysis or liver disease. Mild icterus is the only abnormal
physical finding in Gilberts syndrome (GS). Genetically, this syndrome is due to
a TATA-box polymorphism in the UGT1A1 promoter (most common insertion of
TAn) (116). The frequency for homozygosity for the (TA)7 in normal population
is 10-16%. Serum bilirubin concentrations in GS are usually ≤ 3mg/dL. This
syndrome requires no treatment and does not lead to hepatic damage (131).
1.1.5.2 Disorders leading to conjugated hyperbilirubinemia
Dubin-johnson syndrome
The Dubin-Johnson syndrome is a hereditary deficiency in the excretion of
conjugated bilirrubin by hepatocytes characterized by chronic hyperbilirubine-
mia, alteration in coproporphyrin metabolism, and intracellular deposition of a
dark melanin-like pigment giving the liver a typical black cast (16). Genetically,
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patients have altered ATP-dependent transporter ABCC2 (non sense mutation)
expression, so the biliary excretion of organic anions is impaired (except for bile
acids). Bilirubin glucuronides reflux into blood producing conjugated hyperbiliru-
binemia. Total bilirubin serum reaches between 2 and 5 mg/dL (very rarely up
to 20 mg/dL). Patients present normal liver enzymes values, blood count, lipids
and serum albumin and no risk of fibrosis or cirrhosis development (131).
Rotor syndrome
Rotor syndrome is a rare, benign familial disorder characterized by chronic
fluctuating, nonhemolytic and predominantly conjugated hyperbilirubinemia with
normal hepatic histology (66). In contrast to Dubin-Johnson syndrome, there is
no liver pigmentation. It seems that patients have impaired hepatocellular storage
of conjugated bilirubin, resulting in a reflux into the plasma (131).
1.1.6 Bilirubin Neurotoxicity
To clarify the physiological relevance of the molecular mechanism by which
bilirubin induce neurotoxicity, it is important to understand the particulars of
the bilirubin exposure itself and to relate that exposure to central nervous system
(CNS) injury likely to occur. It is suggested that the risk for neurological damage
is related to the degree and duration of hyperbilirubinemia (128).
In the previous sections the physiological metabolism of bilirubin was de-
scribed, the different ligands of the molecule and the disorders that could be
observed. In this section the molecular mechanism of bilirubin neurotoxicity are
being detailed. The initial injury observed is principally the perturbations of
membrane permeability and function, followed by mitochondrial energy failure
and increase intracellular calcium concentration. All this can proceed to the
activation of proteolytic enzymes and finally resulting in apoptosis or necrosis
depending on the degree of the injury (141).
9
1. INTRODUCTION
The strong affinity of UCB to membranes could result in a conformational
change in the N-methyl-D-aspartate glutamate receptor (NMDA), altering the
glutamate uptake (excessive release and impaired reuptake) over-stimulating the
receptor (excitotoxicity) (51, 59). Once NMDA channels are opened, it leads
to increased intracellular Na+ and Cl−, followed by a Ca+2 influx and Ca+2 re-
lease from intracellular stores producing the activation of Ca+2-dependent en-
zymes that activate apoptosis (by caspase 3) and/or necrosis cell death pathways
(20, 111, 142). There are some controversy about which mechanism occur first.
It hes been proposed that the mitochondrial energy failure with a resultant neu-
ronal depolarization opens the NMDA glutamate channels (99). Others, instead,
consider that UCB may act directly on the neuronal cell membrane and mitochon-
dria to perturb lipid polarity, fluidity, and protein order conducing to collapse of
membrane potential, release of Cytochrome-c and activation of intrinsic apoptosis
mechanisms independent of excitotoxic pathways (76, 114, 141).
Bilirubin neurotoxicity is selective, certain areas of the brain and certain cell
types within these regions are more affected than others. The most vulnerable
regions are the basal ganglia, hippocampus, cerebellum and cochlear nuclei. The
selective affinity of bilirubin for those brain sites is uncertain. The local blood flow
is homogeneous in both human and rodent during the early postnatal development
and is not correlated to the regional susceptibility to UCB (48). Some possible
explanations could be the differences in lipid composition in these areas (21),
accumulation and clearance of UCB (44) and/or immature state of the cells in
these areas. It has been demonstrated that immature neural cells (astrocytes and
neurons) are more susceptible to UCB damage compared to more differentiated
ones. Moreover, among the cell types neurons are more prone to bilirubin induced
cell death, displaying low inflammatory response, whereas astrocytes are more
competent in releasing glutamate and pro-inflammatory (NF-κβ, TNF-α, Il-β
and IL-6) mediators (38).
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1.1.7 Current treatments
Phototherapy is the therapy widely used for hyperbilirubinemia to transform
UCB in the skin to water-soluble isomers, cleared without the need of liver conju-
gation (Fig. 1.4) (13). The efficacy of phototherapy units varies widely because of
differences in light source and configuration. The characteristics of the devices to
contribute to its effectiveness are: the emission of light in the blue-to-green range
that overlaps the in vivo plasma bilirubin absorption spectrum (≈ 460 - 490 nm);
the irradiance of at least 30µW.cm−2.nm−1 (confirmed with an appropriate irra-
diancemeter calibrated over the appropriate wavelength range); the illumination
of maximal body surface (changing the infants posture every 2 to 3 hours may
maximize the area exposed to light.); and the demonstration of a decrease in total
bilirubin concentrations during the first 4 to 6 hours of exposure (should decrease
more than 2mg/dl in serum bilirubin concentration). The initiation and duration
of phototherapy is defined by the specific range of total bilirubin values based on
an infant’s postnatal age and the potential risk for bilirubin neurotoxicity.
The clinical response depends on the rates of bilirubin production, enterohep-
atic circulation, and bilirubin elimination and the degree of tissue bilirubin depo-
sition (135). Moreover, the neonates clinical status during phototherapy should
be followed to ensure adequate hydration, nutrition, and temperature control.
Currently, the administration of albumin prior to phototherapy producing im-
mediate reduction in serum UCB values was also assessed (25, 60). If the UCB
concentrations becomes dangerously high or rise rapidly despite phototherapy,
exchange transfusion (ET) is indicated.
Nowadays, ET has become a rare event in most developed countries. How-
ever, it remains as a frequent emergency rescue procedure for severe neonatal
hyperbilirubinemia in many underdeveloped regions of the world (Fig. 1.5) (98).
Exchange transfusions should lower the blood bilirubin levels sufficiently, quickly
and safely, but also have serious side effects and complications. The mortality
rate in the 80-90’s from the procedure was approximately 0.3-2.0% and signifi-
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cant morbidity was associated with 5-12% of ETs. Complications include cardiac
arrest, thrombosis of the portal vein, graft vs. host disease, coagulopathies, hy-
poglycemia, hypocalcaemia, necrotizing enterocolitis, transmission of infectious
diseases, bleeding, catheter-related complications, apnea and bradycardia with
cyanosis requiring resuscitation (64, 75, 104). Conventionally, exchange transfu-
sion has been performed via a central umbilical venous catheter by pull-push cycle
method. Recently peripheral artery/peripheral vein has emerged as an alterna-
tive, isovolumetric route (Fig. 1.5). The procedure involves incremental removal
of the infants blood having high bilirubin levels and simultaneous replacement
with fresh donor blood providing fresh albumin with binding sites for bilirubin.
Ideally, the infants total circulating blood volume needs to be repaced to have
an efficient ET. Some procedures use 80-90 ml/kg (the estimated blood volume
in a newborn) of donor blood, termed as single-volume blood exchange trans-
fusion (SBVET), others use the doble volume (160-180 mL/kg), double-volume
blood exchange transfusion (DBVET). On the basis of the time constant of the
exchange an SVET is likely to exchange 63% of the infants blood whereas DVET
exchanges 86%. However, because of tissue intravascular dynamics, more biliru-
bin is removed from the infant than the blood volume exchanged during ET (98).
Furthermore, an alternative to classical ET is to add albumin before ET to in-
crease the reserve of albumin providing more binding sites for UCB. However,
this is not yet of routine clinical use as the risk of albumin administration has
not been assessed (92, 124).
New therapies are being developed to treat or prevent newborn of kernicterus.
Metalloporphyrins (Mps) have been assessed as possible compounds to reduce
bilirubin levels in blood. They are structural analogs of heme and their poten-
tial use in the management of neonatal hyperbilirubinemia has been the subject
of considerable research for more than three decades. They are competitive in-
hibitors of heme oxygenase (HO), limiting the enzyme activity in bilirubin pro-
duction and effectively reduce bilirubin formation. Ongoing research continues in
identifying the ideal metalloporphyrins, which are safe and effective, by defining
the therapeutic windows and targeted interventions for the treatment of exces-
sive neonatal hyperbilirubinemia. Although Mps have been studied extensively
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in animal models and some human trials, their safety has not been unequivocally
proven yet, mainly due to the photosensitizing potential of these compounds
(120, 143).
Minocycline, a neuroprotective agent, is effective in neurological disorders as-
sociated to the oxidative stresss and inflammation. The drug is an anti-inflammatory
and anti-apoptotic semisynthetic tetracycline that inhibits the microglia activa-
tion, reducing also for example the cerebellar hypoplasia in Gunn rats (46, 82,
109). However, minocycline has several side effects such gastrointestinal symp-
toms, pediatric tooth discoloration, dizziness (127).
In addition, Brites group has widely studied the effect of glycoursodeoxy-
cholic acid, showing its anti-apoptotic, antioxidant and anti-inflammatory effects
in neural cells (126, 140). Moreover, taurine is another compound of potential in-
terest as a possible anti-inflammatory, anti-apoptotic molecule to treat or prevent
bilirubin neuronal damage (146).
Figure 1.4: Phototheraphy.
Neonatal jaundice is usually a self-limiting, mild disorder. The most commonly used treatment is fluorescent
light exposure, in which the infant is placed under a lamp for a few hours each day. The blue light breaks
down bilirubin into a form the infant liver can process and eliminate (taken from A.D.A.M. encyclopedia).
Even there are many different therapies an important point could be mis-
leading. The decrease of bilirubin in blood may not represent the decrease of
13
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Figure 1.5: Blood exchange transfusion.
Briefly, the infant is laid on his or her back, usually under a radiant warmer. The umbilical vein is catheterized
with a fluid-filled catheter. The catheter is connected to an exchange transfusion set, incorporating lines to
and from a waste container and a pack of donor blood. The ET goes ahead in cycles, each of a few minutes
duration. Slowly the infant’s blood is withdrawn, and the fresh, pre-warmed blood or plasma is injected (taken
from A.D.A.M. encyclopedia).
bilirubin in tissues, particularly in brain (the reservoirs). There is a dynamical
balance between bilirubin concentration in blood and tissues due to reversible
diffusion of bilirubin between them. High levels of bilirubin in blood leads to
a high bilirubin concentration in tissues and viceversa - low level of bilirubin in
blood results in bilirubin counterblow from tissues to blood. This continue un-
til the balance between these two bilirubin is reached (within 5-6 hours) (13).
Considering what mentioned above, bilirubin could continue damaging the brain
during this gap of time. Because of that, therapies that focus on brain bilirubin
clearance/protection should be studied.
1.1.8 Animal models of bilirubin encephalopathy
Two rodents models of hyperbilirubinemia and kernicterus exist. The first one
is the Gunn rat that emerged spontaneously in the late 1936 in a wistar rat colony
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(52). The Gunn rat is characterized by a Ugt1A single base deletion, causing a
frameshift mutation, leading to a stop codon and has been used as animal model
of Crigler- Najjar type I syndrome and neonatal jaundice (22, 121).
Morphologically, the brain is affected almost selectively in jj rat. The hip-
pocampus, all basal ganglia, and most brain stem nuclei are damaged in hiper-
bilirubinemic, with a distribution similar of what seen in humans (121). In con-
trast to human kernicterus, cerebellar hypoplasia is a prominent feature of biliru-
bin damage in Gunn rat, detected in rarely in babies and quite exclusively in
preterms (23, 117, 121).
It has been suggested a developmental dependence of cerebellar hypoplasia in
Gunn rat (principally Purkinge cell and granular lost) (23, 117). It is known that
cerebellum develops after the birth (34), and that cerebellar hypoplasia in jj rat
begins largely after 8 post-natal days (23), consistent with the critical period for
bilirubin-induced cerebellar hypoplasia identified at P6-10 (110, 117, 134). The
principal characteristic of this model could be correlated with hyperbilirubinemic
pre-term newborns (4, 12).
The second one is the mouse model, created by introducing the stop codon in
the Ugt1A1 gene (15). This mice also present a cerebellar architecture affected by
bilirubin toxicity, with reductions in Purkinje cell number and dendritic arboriza-
tion. Even both models have similar gene defect, they behave very differently.
Mutant mice die within 10 days, whereas Gunn rat pups survive.
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1.2 Brain
1.2.1 Cerebellum and cerebral cortex
The central nervous system consists of the brain and spinal cord, while the pe-
ripheral system consists of all the neural (nerve) tracts that lie outside these cen-
tral tissues and connect the rest of the body. The human brain weights between
1200 a 1400gr in adults, while 350-400gr in newborns. It consists of three major
divisions: 1) the massive paired hemispheres of the cerebrum; 2) the brain-stem,
consisting of the thalamus, hypothalamus, epithalamus, subthalamus, midbrain,
pons, and medulla oblongata, and 3) the cerebellum (Fig. 1.6). Due to the com-
plexity of the whole brain structure that define each region, we only focus our
attention on the description of the areas considered as target for our study, the
cortex and cerebellum.
Cerebellum (“little brain”), is located at the base of the brain that lies above
the brain-stem. It regulates a range of functions including motor control, at-
tention and cognition. The gross anatomy of the cerebellum is characterized by
transverse fissures of different depths, which subdivide the cerebellum into lobes,
lobules and folia (leaflets). The cerebellum is covered with a cortex; its central
white matter contains the cerebellar nuclei. The structure of the cerebellar cortex
appears to be uniform throughout the cerebellum. The cortex has a very complex
structure, being made up of many different kinds of neurons, but it appears to
be composed of only three layers. The main neurons of the cerebellar cortex are
the Purkinje cells and the granule cells. With regard to Purkinje cells, they form
structures subdivided into multiple paired, narrow longitudinal zones, and are
orientated perpendicularly to the parallel fibres. The other types, the granular
cells, are small, extremely abundant and located in the granular layer, underneath
the Purkinje cells. Astrocytes are estimated to comprise only the 20% of cells in
the cerebellum, while neurons represent the 80% (58, 108).
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The cerebral cortex is the outermost layered structure of neural tissue of the
brain, is divided into two cortices, covering the left and right cerebral hemispheres.
The cerebral cortex plays a key role in memory, attention, perceptual awareness,
thought, language, and consciousness. It consists of up to six horizontal layers,
each with a different composition in terms of neurons and glial cells. It is impor-
tant to note that the cortical layers are not simply stacked one over the other.
A characteristic connections between different layers and neuronal types exists,
which span all the thickness of the cortex. The two principal types of neurons that
are present in cortex are the excitatory pyramidal neurons (≈80% of neocortical
neurons) and inhibitory interneurons (≈20%). The neurons are also arranged in
vertical structures called neocortical columns, each column typically responds to
a sensory stimulus representing a certain body part or region (97, 108).
Figure 1.6: Sagital diagram of the rat brain
(Taken from http://www.livescience.com/29365-human-brain.html)
1.2.2 Astrocytes cells
Astrocytes are a type of glial cells; they are star shaped, multifunctional and
indispensable for neuronal survival and function. They provide the migratory
scaffold for neurons; represent the major source of extracellular matrix proteins,
adhesion molecules and glycogen. Also, they contribute to the formation and
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preservation of a secure blood-brain barrier (BBB). Astrocytes control ionic and
osmotic homeostasis, remove neurotransmitters from the synaptic cleft, and pro-
duced a variety of tropic factors. They have important roles in development and
plasticity of the central nervous system by modifying the growth of axons and
dendrites, and regulating synapse formation (94). In most instances, protoplasmic
astrocytes predominate in gray matter and fibrous astrocytes are most common
in white matter. The first ones processes contact blood vessels and form multiple
contacts with neurones. The fibrous ones have long, thin, less branched processes.
Another group are the radial glial cells, which are bipolar cells each with an ovoid
cell body and elongated processes. Radial glia are a common feature of the de-
veloping brain, which assist in neuronal migration. After maturation, disappear
from many brain regions and transform into stellated astrocytes. The cerebellum
contains specialized semi-radial glia called Bergmann glia. They have relatively
small cell bodies and 3-6 processes that extend from the Purkinje cell layer to
the pial surface. The processes of Bergmann glial cells are extremely elaborated,
and they form close contacts with synapses formed by parallel fibres on Purkinje
neuron dendrites; each Bergmann glial cell provides coverage for up to 8000 of
such synapses. Furthermore, the velate astrocytes are found in the cerebellum,
where they form a sheath surrounding granule neurones; each velate astrocyte
enwraps a single granule neurone. In cortex a particular type of astrocytes are
present, the interlaminar astrocytes (observed in higher primates) that are small
glial cells, similar to protoplasmic astrocytes. Their characteristic peculiarity is
a very long single process, reside in the upper cortical layers, and extend long
GFAP positive processes through cortical layers 2-4 (77). The amount of glial
cells in cortex is higher compared to cerebellum that contain more neurons (9).
These cells may have either a neuroprotective or a neurotoxic role, leading
the destiny of the neurons. Injuries in astrocytes function have been recognized
as highly contributing to neuronal dysfunction (7). Astrocytes are known to be
a heterogeneous cell population based on their morphology and the expression of
different sets of receptors, transporters, ions channels and other proteins (43, 87).
Similarly to neurons, astrocytes exhibited an age-dependent sensitivity to UCB
toxic effects (38).
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As these cells could modulate the vulnerability of neurons to injury (39, 143).
Astrocytes should be considered one of the targets when searching for novel ther-
apeutics for preventing neurological sequelae by UCB.
1.3 Cyotochrome P450 enzymes
Cytochrome P450 enzymes (Cyps) are heme-containing superfamily that cat-
alyze the detoxification and bioactivation of a wide range of xenobiotics and
endogenous compounds such as antibiotics, steroid, fatty acids, vitamins, among
others. Heme proteins contain the heme prostatic group consisting of a Fe+2
(ferrous) ion in the centre of a porphyrin, a large heterocyclic organic ring made
up of four pyrrolic groups joined together by methene bridges. The heme iron
serves as a source or sink of electrons during electron transfer or redox chem-
istry. These enzymes are potent oxidants that are able to catalyze several re-
actions such hydroxylation of saturated carbon-hydrogen bonds, the epoxidation
of double bonds, the oxidation of heteroatoms, dealkylation reactions, oxidations
of aromatics, and so on (26, 88). The principal mechanisms induced by xeno-
biotics are monoxygenation and uncoupled activity. The first mechanism the
NADPH/O2 stoichiometry is 1 instead the second the ratio is 2. Moreover, the
latter mechanism the molecular oxygen is fully reduced presumably to water (Fig.
1.7).
These enzymes are present in all organism including viruses. Genes encoding
Cyp enzymes, and the enzymes themselves, are designated with the abbreviation
Cyp, followed by a number indicating the gene family, a capital letter indicat-
ing the subfamily, and another numeral for the individual gene. The conven-
tion is to italicize the name when referring to the gene. For example, CYP1A1
is the gene that encodes the enzyme CYP1A1 (all capital letters for human,
in rodents the first letter in uppercase and the remaining letters in lowercase).
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The current nomenclature guidelines suggest that members of new Cyp fami-
lies share ≥40% amino acid identity, while members of subfamilies must share
≥55% amino acid identity (http://drnelson.uthsc.edu/CytochromeP450.html and
http://www.cypalleles.ki.se/).
Cytochromes P450 play a central role in the Phase I metabolism of drugs
and other xenobiotics induced by Aryl hydrocarbon receptor (AhR) (53, 78).
The AhR bind to many compound such as 2,3,7,8-tetrachlorodibenzo-p-dioxin
(TCDD), 3-Mehtylcholathrene (3-MC), β-naphtoflavone (βNF, natural occurring
dietary chemical) to produce the dimerization of AhR with the AhR nuclear
translocator (Arnt). The heterodimer binds to the xenobiotic response elements
(XRE) in the distal and proximal promoter regions of the Cyp1A gene (137).
In addition, Cyp1A activation may occur in a ligand-independent AhR manner,
suggesting a cross-talk between AhR and other signaling pathways (74).
It is estimated that Cyps can metabolize up to two-thirds of drugs present
in humans liver. Even it is believed that the liver is the main site of expression,
these enzymes are also present in others tissues such as lungs, spleen, brain,
kidney (49, 91, 122).
1.3.1 Cytochrome P450 enzymes in liver
The liver is one of the vital organs in vertebrates, is characterized principally
by the detoxification of drugs, protein synthesis and the production of biochem-
icals for the digestion. There are many Cyps involved in the metabolism of
xenobiotics like CYP1A, CYP2C and CYP2E among others in humans. The
constitutional factors such as age and gender, exposure to environmental agents
like contaminants, cigarette and ethanol and moreover liver diseases may modu-
late their expression (47). Cyps induction in in vivo and in vitro models has been
widely studied, using different inducers (β-naphtoflavone, 3-MC, TCDD, omepra-
zole, phenobarbital) in rats and in hepatoma cell lines (28, 71, 80, 81, 107).
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Figure 1.7: The cytochrome P450 catalytic cycle.
The different steps involved in monooxygenation, “uncoupled” activity and “oxidase” activity of Cytochrome
P450. The compound A-B mean any compound able to bind the active site of the enzyme. Taken from De
Matteis et. al (26).
Moreover, cytochrome P450 enzymes have been linked to bilirubin oxidation.
Firstly observed in 1978 by Kapitulnik (71) in treated Gunn rats (animals that
lack the expression of UGT1A1 enzyme) by TCDD. Treated rats had lower lev-
els of bilirubin in blood. What is more interesting, in 1993 the same group
analyzed the Gunn rats without any treatment and revealed that jaundiced new-
borns rats have higher liver expression of Cyp1A1 and Cyp1A2 compared to the
non jaundiced littermates, proposing them as a compensatory mechanims in UCB
clearance.
De Matteis group, corroborated this hypothesis analyzing the capacity of
Cyp1A1 and Cyp1A2 to oxidize bilirubin in rat liver treated with 3-MC and
TCB or TCDD or in chicken embryos treated with βNF (27, 29, 145). In addi-
tion, Abu bakar, showed bilirubin oxidation by Cyp2A5 (homologous CYP2A6
in human; Cyp2A3 in rat) in liver mice and CYP2A6 in HepG2 hepatoma cell
line (1, 2, 3).
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Additonal studies demonstrated that liver Cyps are more prone to oxidize
bilirubin when exposed to planar or non-planar polyhalogenated biphenyl such
as 3,4,3,4 tetrachlorobyphenyl (TCB). Depending on the Cyp and the polyhalo-
genated biphenyl interaction in the active site of the enzyme, could lead to the
inhibition of its monooxygenase activity and increased production of reactive
Oxygen species (ROS) by an uncoupling mechanism (28, 119). This ROS may
be the responsible of bilirubin oxidation.
1.3.2 Cyotochrome P450 enzymes in brain
The neural tissue contains its own unique set of cytochrome P450 genes that
are regulated in a manner that is distinct from their molecular regulation in
peripheral tissue. These particular characteristics allow this family of proteins
and their metabolites to perform vital functions in the brain such as neurotrophic
support, neuroprotection, control of cerebral blood flow, temperature control,
neuropeptide control, regulation of neurotransmitter levels and other functions
important in brain physiology, development and disease(122). On the other side,
imposed to assess the ability in bilirubin oxidation.
Although Cyps in brain occur at low levels in comparison of liver, it has been
reported that the amount of Cyps in specific cells can be as high as or even higher
than the level in hepatocytes (90, 132). The brain complexity and cellular hetero-
geneity is reflected in the regional and cellular differences observed in Cyps distri-
bution. This distribution may play a critical role in the activation of degradation
of drugs and chemicals in specific areas and cell type. The constitutive expression
of Cyps in neuron are higher than glial cells but the inducibility is higher in the
latter ones indicating again a potential role in toxication-detoxication mechanism
(33, 56, 73). Studies on the regional and cellular localization of Cyps in the brain
have many discrepancies, principally by the diverse techniques used and the high
degree of homology between Cyps. Some studies stated that the higher amount
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of Cyps is in mitochondrial membranes and others microsomes fractions. More-
over some studies showed that even the mitochondria Cyps content is higher the
major activity is in microsomes (10, 49, 61).
Cytochrome P450 expression in newborn is still not known, but it is believed
lower in comparison with an adult. CYP1A1 has been shown to be present in
human adult brain localized in cortical region, midbrain, basal ganglia, hippocam-
pus and cerebellum. CYP1A2 has been found in most brain regions (10, 37, 40).
In rat models has been observed that young rats and the corresponding cells are
more sensible to bilirubin than older ones (38). This could be in concordance with
the maturation of Cyps expression observed in Gunn rats brain in our laboratory
(unpublished results) and in liver by kapitulinik (70) as alternative explaination
to ABCs mediated protection.
In addition, in our laboratory the tissue bilirubin dinamics in brain were ana-
lyzed in Gunn rats treated with sulphadimethoxine, a bilirubin displacing agent.
Showing that in cortex and superior colliculus, not damaged regions, Cyp1A1,
Cyp1a2 and Cyp2A3 mRNA induction was an early event in concordance with the
bilirubin clearance. While in cerebellum and inferior colliculus, damaged regions,
the Cyps induction had a delay of 24h and lower in extent, again in concordance
with the bilirubin content and clearance (44).
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2.1 Aims
Bilirubin encephalopathy may occur when bilirubin blood concentration rises
and accumulates in the body. If the concentration reaches to high levels brain
damage could be produced. Bilirubin neurotoxicity is selective; certain areas of
the brain and certain cell types within these regions are more affected than others.
The most vulnerable regions are the cerebellum, basal ganglia, hippocampus and
cochlear nuclei.
Between the cell types, neurons are more prone to bilirubin induced cell
death, whereas astrocytes are more competent in releasing glutamate and pro-
inflammatory cytokine (41, 42). Moreover, the greater magnitude of induction of
Cyp1A in glial cells in comparison to neuron (73), suggest that these cells may
have a potential role in detoxication mechanism. Astrocytes are known to be a
heterogeneous cell population based on their morphology and the expression of
different sets of receptors, transporters, ions channels and other proteins (87).
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Being different the “astrocytes types” between the regions. Based on these con-
siderations glial cells could overcome or modulate the UCB toxicity in specific
brain regions protecting the neurons located. For this study an in vitro model
of primary culture of astrocytes from two different regions (Cortex; not damaged
and Cerebellum; damaged) was used in order to assess their role in bilirubin
oxidation.
The aims of my PhD thesis are:
• Analyze the inducibility of brain Cyps enzymes, by a known inducer, βNF
in cortex and cerebellum astrocytes.
• Select the optimal conditions.
• Assess the capacity of induced Cyps to oxidize bilirubin.
• Evaluate the protective effect of Cyps induction by challenging with high
concentrations of bilirubin (140nM; 24h).
• Evaluate bilirubin (140nM; 2h) capacity to induce Cytochrome P450 en-
zyme (mRNA and activity) in cortex and cerebellum derived astrocytes.
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3.1 Chemicals and reagents
Dulbecco’s Modified Eagle Medium low glucose (DMEM LG) and gentamycin
50mg/mL solution were obtained from Invitrogen, Life technologies Corporation
(Grand Island, NY). Dulbeccos Modified Eagle Medium (DMEM) from Euroclone
(Milano, Italy). Fetal bovine serum (FBS), trypsin from bovine pancreas, Dul-
becco’s phosphate buffered saline (PBS), unconjugated bilirubin (UCB), 3(4,5-
dimethiltiazolil-2)-2,5 diphenil tetrazolium (for MTT assay), dimethyl sulfoxide
(DMSO), trypan blue solution (0.4% w/v in PBS), β-naphtoflavone (βNF), re-
sorufin sodium salt, 7-ethoxyresorufin (EROD assay), 7-methoxyresorufin (MROD
assay), β-Nicotinamide adenine dinucleotide 2’-phosphate reduced tetrasodium
salt hydrate (NADPH), 3,4, 3,4-tetrachlorobiphenyl (TCB), and fluorescamine
and fluvoxamine maleate (FVX) were purchased from Sigma Aldrich (St. Louis,
MO, USA). All chemicals and solvents were of analytical grade and were obtained
from common commercial sources.
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3.2 Culture and treatment of Huh7 and HepG2
cells
The Huh7 is a well differentiated hepatocytes derived cellular carcinoma cell
line that was originally taken from a liver tumor in a 57-year-old Japanese male
in 1982. They are epithelial-like cells growing as 2D monolayers (fig 3.1). HepG2
cell line was derived from the liver tissue of 15-year-old male with differentiated
hepatocellular carcinoma. HepG2 are adherent, epithelial-like cells growing as
monolayers and in small aggregates (fig 3.2).
Huh7 and HepG2 hepatocellular carcinoma cells were cultured in DMEM
containing 10% FBS, 2mM L-Glutamine and 1% of penicillin/streptomycin. The
cells were kept in an atmosphere of 5% of CO2 at 37
◦C in a humidified incubator.
Seeded Huh7 cells (20000cell/cm2) were treated with a cytochrome P450 en-
zymes known inducer, βNF, at different concentrations and times of exposure
(2.5, 5, 10, 20 µM of βNF dissolved in DMSO, stock solution 20mM and for 1, 4,
6, 24h). HepG2 cells (35000cell/cm2) were treated with 20µM of βNF for 24h as
described by Krusekopf et al. 2003 (81). Control cells were treated with DMSO
only (final DMSO concentration less than 0.5%).
Figure 3.1: Morphology of Huh7 cells.
Phase contrast picture of Huh7 cells in culture.
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Figure 3.2: Morphology of HepG2 cells.
Phase contrast picture of HepG2 cells in culture.
3.3 Animals
Wistar HanTM Rats (2 day old: P2) of both sexes were obtained from the
animal facility of the Department of Life sciences of Trieste University (Italy),
after regular communication to the Competent Authorities (20-9-2011). Animal
care and procedures were conducted according to the guidelines approved by the
Italian law (decree 116-92) and by the European Communities Council Directive
86-609-ECC. As animals were used as “organ donor” no additional permission
was required. All effort to minimize the sufferance and the number of animals
used were adopted, in respect to the “3R” rules.
3.4 Brain dissection, primary astrocytes culture
Six P2 wistar rats were used for primary culture of astrocytes as described
previously by Booher (1972) (14) with some modification. Briefly, animals were
sacrificed by decapitation; their brains were rapidly excised and placed in DMEM
LG culture medium. Under the stereomicroscope the cortex (Cx) and cerebel-
lum (Cll) were immediately dissected, cleaned from meninges and choroid plexus.
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The different parts were collected in DMEM LG supplemented with 1% of peni-
cillin/streptomycin and cut in small pieces. Cells were mechanically dissociated
by forcing the tissue through a 70µm nylon cell strainer (352350, BD Biosciences,
Milan, Italy) with 5 or 3 mL of DMEM supplemented by 10% of heat-inactivated
FBS, 50µg/mL gentamycin. The cell suspension was continuously dissociated by
a 5mL pipette to avoid cells aggregates. The latter suspension was diluted 1
4
and
cells were seeded at 1.2 105 cells/mL in 6 well plates or flask 75 cm2. Astrocytes
were incubated in culture medium in an incubator at 37◦C in an atmosphere
of 95% air 5% CO2, with 90% of humidity (Fig 3.3 and 3.4). The purity of
the astrocytes cultures were determined by immunocytochemical staining using
the astrocytes marker glial fibrillary acidic protein (GFAP; polyclonal rabbit anti-
GFAP Dako Cytomation Z0334, Denmark) vs. Hoechst staining of nuclei. Briefly,
Astrocytes were grown on a glass coverslip, fixed with paraformaldehyde (PFA)
4% in phosphate buffer, blocked with normal goat serum 5% in 5%BSA, 0.3%
Triton X100 in PBS. Anti-GFAP was diluted 1:1000 ON at 4◦C and secondary an-
tibody Anti-Rabbit Alexa fluor 1:1000 (Alexa fluor 488, Life technologies, Milan,
Italy) for 2h at room temperature. Cells were then washed and incubated with
Hoescht (0.1µg/mL in PBS) for 30 min. Finally mounted on a glass microscope
slide.
Experiments were performed within 15 days in vitro (div), when 90% of con-
fluence was reached.
3.5 UCB solutions and Bf measurements
The free bilirubin concentration (Bf) in DMEM medium was evaluated using
the modified horseradish peroxidase assay as described by Roca (5, 113).
Unconjugated Bilirubin (UCB) was purified as described by Ostrow and Muk-
erjee (100), divided into aliquot, and stored at -20◦C till use. Before each treat-
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Figure 3.3: Morphology of Astrocytes derived from Cerebellum.
Phase contrast picture of Cerebellar cells in culture.
Figure 3.4: Morphology of Astrocytes derived from Cortex.
Phase contrast picture of Cortex cells in culture
ment, an aliquot was dissolved in DMSO (0.3µL of DMSO per µg of UCB), and
diluted with culture medium containing 10%FBS (Sigma-Aldrich; St. Louis, MO,
USA; containing 25.6µM BSA). Experiments were performed with a final UCB
concentrations of 25µM, yielding to a free unbound UCB concentrations (Bf) of
140nM representing a toxic dose.
In order to standardize DMSO related effect, control cells were incubated with
medium containing DMSO 0.5% (the amount of DMSO needed to dissolve UCB
25µM). To minimize photodegradation, all the experiments were performed under
light protection (dim lighting and vials wrapped in aluminum foil).
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3.6 Astrocytes treatment conditions
Astrocytes primary cultures were grown for 12-15 div in the corresponding
medium, and daily monitored. Cells were washed once with PBS and different
treatments were assessed.
First, to analyze the inducibility of bCyps it was used a known inducer, βNF,
at different concentrations (2.5; 5; 10; 20 µM of βNF, dissolved in DMSO; stock
solution 20mM) and timings (1; 6; 24h).
Second, bilirubin oxidation capacity was assessed in membrane fraction of
treated astrocytes for the optimal conditons.
Third, to evaluate if Cyps could protect astrocytes from UCB damage a two
part treatment was performed. Initially, Cx and Cll astrocytes were treated
with βNF optimal condition for Cyp1A1 or Cyp1A2 and with or without TCB
(3.42µM). Then, once Cyps were induced, cells were loaded with bilirubin 25µM
(Bf: 140nM) for 24h, as it is known that at this condition cells viability is reduced
between 60-70% (data obtained in our lab). For this treatments control cells were
exposed only with DMSO (final concentration equal or less than 0.5%) and cells
with only bilirubin.
Finally, in order to evaluate the capacity of bilirubin to induce bCyps, astro-
cytes were loaded with bilirubin 25µM (Bf: 140nM) for 2h.
3.7 Viability tests
MTT and Trypan blue assays were used to analyze the vitality of the cells after
treatment. MTT allow to evaluate the mitochondrial activity by the reduction
of 3(4,5-dimethyltiazolyl-2)-2,5 diphenyl tetrazolium (MTT), a monotetrazohum
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salt, to a blue formazan product (31, 96). Trypan blue (TB) test assess the
membrane integrity. This method is based on the principle that viable cells do
not take up the dye, whereas non-viable cells do.
For MTT test, cells were washed once with PBS, then added the MTT solu-
tion (Stock solution 5mg/mL in PBS pH7.40) diluted to 0.5mg/mL in the cor-
responding treatment medium immediately before the treatment. The cells were
incubated for 1h at 37◦C. After the incubation, formazan crystals were dissolved
by adding 0.5mL of DMSO with gentle shaking. The absorbance was measured
at 570nm in a LD 400C luminescence Detector (Beckman coulter, Milan, Italy).
TB assay was performed by harvesting cells, thus diluting the cells suspen-
sion 1:1 with trypan blue dye (Stock solution: 0.4% in PBS). The hemocytometer
was loaded and examined immediately under a microscope. Both blue staining
cells (dead) and unstained cells (living) were counted. Each square of the hemo-
cytometer represents a total volume of 0.1 mm3 or 10−4 cm3. Since 1 cm3 is
equivalent to approximately 1 mL, the subsequent cell concentration per mL is
determined by the following calculation: the average count per square × dilution
factor × 104. For the cell viability (%) = total viable cells (unstained) / total
cells (stained and unstained) × 100. Each viability was expressed as percentage
of control cells (with vehicle, DMSO).
3.8 Real-time RT-PCR
The mRNA expression of Cyp1A1/CYP1A1, Cyp1A2/CYP1A2, Cyp2A3/
CYP2A6 and Ugt1A1/UGT1A1, Nrf2 and Ahr genes (lowercase for rats, up-
percase for human genes) was analyzed by quantitative RT-PCR. Total RNA of
astrocytes primary culture and Huh7/HepG2 cells were extracted using Eurogold
RNA Pure reagent (Euroclone, Milan, Italy).
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Retrotranscription of total RNA (1µg) was performed with High Capacity
cDNA Reverse Transcription Kit (Applied biosystems, Monza, Italy) according
to the manufacturers instructions. The reaction was run in a thermal cycler
(Gene Amp PCR System 2400, Perkin-Elmer, Boston, MA, USA) at 25◦C for 5
min, 37◦C for 120 min, and 85◦C for 5 min. The final cDNA was conserved at
20◦C until used.
For the quantitative PCR, primers were designed using the Beacon designer
8.1 software (Premier Biosoft International, Palo Alto, CA, USA) on rats or
human sequences available in GenBank (see table 3.1). The reaction was per-
formed on 25ng of cDNA, with the corresponding gene-specific sense and anti-
sense primers 250nM (with the exception of Ahr concentration of 300nM), with
1x iQ SYBER Green Supermix (Bio-Rad Laboratories, Hercules, CA, USA) in a
final volume of 15µL (Ahr 20µL). Reactions were run on an iCycler iQ thermocy-
cler (Bio-Rad Laboratories, Hercules, CA, USA). The thermal cycler conditions
consisted of 3 min at 95◦C and 40 cycles each at 95◦C for 20s, 60◦C for 20s, and
72◦C for 30s.
The PCR was performed in 96-well plates; each sample was analysed in dupli-
cate. Standard curves using a calibrator cDNA (chosen among the cDNA samples
from astrocytes and hepatoma cell line without treatment) were prepared for each
target and house-keeping gene. Melting curve analysis was performed to assess
product specificity. The relative quantification was made using the iCycler iQ
Software, version 3.1 (Bio-Rad Laboratories, Hercules, CA, USA) by the Pfaffl
modification of the ∆∆CT equation (CT: cycle number at which the fluorescence
passes the threshold level of detection) (105), taking into account the efficiencies
of the individuals genes. The results were normalized to the chosen housekeeping
genes and the initial amount of the template of each sample was determined as
relative expression vs. one of the sample chosen as reference which is considered
the 1x sample.
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3.9 Membrane fraction preparation
Treated astrocytes were harvested, washed and pelleted, then were homoge-
nized by a gentle manual method using a glass on glass Dunce homogenizer (Ar-
tiGlass, Pordenone, Italy) in a homogenization buffer (Tris HCl 10mM; EDTA
1mM; DTT 0.5mM; Protein Inhibitor 0.1mM pH:7.4). The homogenate was
centrifuged at 900g using a Beckman Allegra 25R (Beckman, Milan, Italy) to
eliminate the debris. The supernatant was directly applied to ultracentrifugation
at 110000g for 60min using a Beckman LE-80K Optima; rotor 70.1 Ti (Beck-
man, Milan, Italy). All procedures were performed at 4◦C. The resulting pellet
was designated as a membrane fraction, under this condition microsomes are not
separated from nuclear membranes and mitochondria (89). Membrane fractions
were stored at -80◦C with 20% of glycerol till use.
3.10 Enzymatic assays
EROD and MROD assays were performed to assess the Cyp1A1 and Cyp1A2
activity by the O-dealkylations of ethoxyresorufin and methoxyresorufin, respec-
tively, accordingly to the method described by Meyer et al. (89) with some modifi-
cations. Briefly, the membrane fraction of treated astrocytes primary culture were
preincubated with 5µM of the substrate (ethoxyresorufin or methoxyresorufin) in
a 50mM phosphate buffer with 2mM of MgCl2 for 5 min at 37
◦C. NADPH (1µM
final concentration) was added and the reaction was allowed to proceed at 37◦C
in darkness measuring every 5min fluorescence of the product (resorufin) with the
Perkin Elmer Envision multilabel plate reader (excitation/emission wavelength
535/590nm) (PerkinElmer, Milan Italy). It must be notice that the amount
of membrane fraction needed to perform these experiments was high, at least
40µg each well (100µL) to have a proper signal. For the HepG2 cell line, the
same protocol was applied in intact cells as described by Zhang (147). Samples
were assessed in duplicates and the amount of resorufin produced in the samples
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was calculated based on a standard curve developed from a range of product
(0-250nM) concentrations in the presence of the substrate and NADPH.
Results were normalized to protein content. Protein content was measured
in every single well by the addition of fluorescamine in DMSO (4mg/mL). Fluo-
rescamine reacts with primary amines in proteins forming a fluorescent product
(excitation/emission wavelength 390nm/460nm). The results were calculated by
regression curve analysis as respect the fluorescence generated by the standard
curve of BSA (0-100µg) in the phosphate buffer with the substrate.
To analyze the specificity of the enzymatic tests, MROD assay was inhibited
by the addition of fluvoxamine 0.25µM to the samples. It is known that at low
concentrations (0.25µM) inhibits only Cyp1A2 activity, while at higher concen-
trations (100µM) both Cyps are inhibited (Ki Cyp1A1 33000nM and Ki Cyp1A2
40nM) (103, 133).
3.11 Bilirubin disappearance activity
The rate of HepG2/astrocytes bilirubin degradation was determined as de-
scribed previously by De Matteis and Abu-bakar (3, 26) with some modifications.
Briefly, the enzymatic incubation mixture contained the following components:
Tris-HCl 100mM pH=8.2, KCl 26mM, EDTA 2mM and membrane fraction of
induced and non-induced astrocytes (40µg total protein/100µL). The final con-
centration of bilirubin employed was 15µM. After 5 min pre-incubation with
bilirubin, NADPH (final concentration 137µM) was added to the sample to start
the reaction. The loss of absorbance of bilirubin and NADPH was followed with
the PerkinElmer Envision multilabel plate reader every 3min at 440 and 340nm.
For the bilirubin calculations was used mM values of 64.34 for HepG2 and 21.6
and for astrocytes.
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3.11.1 TCB addition
It is been studied that for Cyp1A1 to be oxidative active, needs the addition of
coplanar halogenated biphenyl substrate like 3,4, 3,4-tetrachlorobiphenyl (TCB;
3.42µM). To corroborate this in brain, the same protocol described above was
performed also with the addition of TCB to the microsomal incubation together
with NADPH (30, 145).
3.12 Western blot
After protein quantification of the membrane fraction from Cx and Cll astro-
cytes by fluorescamine protocol (described above), 40µg of each sample (rat liver
control 20 µg) were denatured with 10% β-mercaptoethanol in Laemmli loading
buffer (62.5 mM Tris-HCl, pH 6.80; 25 % glycerol, 2 % SDS, 0.01 % bromophe-
nol blue) by 10 min boiling in water bath. Thus samples were separated by
SDS-PAGE 12% polyacrylamide gels. Molecular weight standards (10-250 kDa,
SM1811 Fermentas, M-medicals, Milan, Italy) were used to assess the proteins
molecular weights. Proteins were electro-transferred with a wet blotting system
(BioRad Laboratories, Hercules, CA, USA) at 100 V for 1h onto PVDF mem-
brane (0.2µm; Whatman Schleicher and Schuell, Dassel, Germany) in transfer
buffer (25mM Tris-Base; 192M glycine, 0.1% SDS; 20% methanol). Efficienty of
the transfer was assessed by lack of Coomassie blue coloration of the gel after
blotting and Ponceau staining of PVDF membrane.
Membranes were saturated for 1h in blocking solution 4% BSA in T-TBS
(20mM Tris-Base; 500mM NaCl, pH 7.40, 0.2% Tween 20) at room temperature
(RT) and incubated overnight at 4◦C with the primary antibody anti-Cyp1A1 e
anti-Cyp1A2 ([H-70] sc-20772 and [3B8C1] sc-53614, respectively. Concentration
200g/mL, dilution 1/100, Santa Cruz Biotechnology, Santa Cruz, CA, USA; ) in
the same solution. After three washing, membranes were incubated for 1h at RT
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with peroxidase-conjugated anti-rabbit secondary antibody (P0448, 0.04 µg/mL,
Dako, Glostrup, Denmark).
Protein bands were detected by peroxidase reaction according to the manu-
facturers protocol using a chemiluminescence procedure (Millipore, Billeria, MA,
USA) and visualized on X-ray films (BioMax Light, Kodak Rochester, NY, USA).
3.13 Statistical analysis
The statistical significance of difference between control and treated cells was
evaluated by paired two tailed test using InStat 3.06 (GraphPad software, San
Diego, CA, USA). Differences were considered statistically significant at a p value
≤0.05. All results were expressed as mean ± S.D.
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4Results
4.1 Hepatic cell culture
4.1.1 Huh7 mRNA Cyps inducibility by βNF
The hepatic cell line Huh7 was grown in completed DMEM medium till 80-
90% of confluence, and then treated with βNF at different concentrations (2.5,
5, 10, 20µM) and timing 1, 4, 6 and 24h. After the treatment, mRNA was
extracted and qRT-PCR was performed. CYP1A1, CYP1A2 and CYP2A6 (in
humans, corresponding to Cyp2A3 in rat) mRNA was analyzed. As the Huh7 is
an hepatic line (our liver model), it should express the bilirubin conjugating gene
UGT1A1. mRNA expression was analyzed to assess their possible induction by
the drug (Fig. 4.1).
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Figure 4.1: mRNA expression in Huh7 treated βNF.
CYP1A1, CYP1A2 and UGT1A1 mRNA expression of Huh7 cells treated with βNF at different
concentrations and timing (2.5, 5, 10, 20µM and 1, 4, 6, 24h, respectively). Control cells were exposed to the
vehicle (DMSO). Data are mean SD of 4-5 independent experiments. Statistical analysis is detailed in Table
4.1.
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Huh7
CYP1a1 µM βNF
Hours 2.5µM 5µM 10µM 20µM
1h ns ns ns ns
4h ns ns ns ns
6h ns p≤0.05 p≤0.05 p≤0.05
24h p≤0.05 p≤0.01 p≤0.05 p≤0.001
CYP1A2 µM βNF
Hours 2.5µM 5µM 10µM 20µM
1h ns ns ns ns
4h ns ns ns ns
6h p≤0.05 p≤0.05 p≤0.05 p≤0.05
24h ns p≤0.01 p≤0.01 ns
UGT1a1 µM βNF
Hours 2.5µM 5µM 10µM 20µM
1h ns ns ns ns
4h ns ns ns p≤0.05
6h ns ns ns p≤0.05
24h p≤0.001 p≤0.001 p≤0.01 p≤0.05
Table 4.1: Stadistic analysis of Huh7 mRNA treated with BNF
CYP1A1, CYP1A2 and UGT1A1 mRNA expression statistical analysis of treated Huh7 cells with different
concentrations and timing of βNF (2.5, 5, 10, 20µM and 1, 4, 6, 24h, respectively).
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The CYP1A1 mRNA induction by βNF was not significantly upregulated at 1
and 4h. The expression was significantly induced as increase the concentration of
the drug after 6 and 24h, with the higher induction at 20µM;24h (10fold p≤0.001).
CYP1A2 mRNA was not induced after 1 and 4h, while after 6h the induction
was significant at all the βNF concentrations, reaching a maximum of 28fold at
20µM. After 24h of treatment the mRNA expression return to similar values of
1 and 4h.
The UGT1A1 mRNA was also analyzed. The conjugating enzyme mRNA
level was significantly upregulated (2 folds) after 24h, when exposed to 2.5 -
10µM of βNF.
Finally, the CYP2A6 was not expressed in this cell line. To confirm the
absence of this Cyp were used three different primer pairs, comprising the one
detailed by Abu Bakar (2).
Moreover, after each treatment the viability was analyzed by two different
methods, Tripan blue and MTT. TB showed that the treatment was not harmful
for the cells (with the exception at the higher concentration after 24h) (Fig.4.2),
while by MTT a decrease in viability as we increase the drug concentration and
time of exposure was observed, having a significant drop at the higher concentra-
tion (4, 6 and 24h).
The optimal condition were selected taking in account the mRNA and the
viability. For this reason, the 20µM;24h treatment was excluded (where viability
drop). For Cyp1A1 the optimal condition selected was 10µM of βNF for 24h;
the mRNA was upregulated only 3folds. For Cyp1A2 the optimal condition was
20µM of βNF for 6h (28fold).
44
4.1 Hepatic cell culture
Figure 4.2: Viability percentage in Huh7.
Cells treated with different concentrations of βNF (2.5, 5, 10, 20µM) analyzed at different timing (1, 4, 6, 24h).
Control cells were treated with the vehicle (DMSO). Data are mean SD of 4-5 independent experiments.
4.1.2 HepG2 mRNA Cyps induction by βNF
HepG2 was the other hepatic cell line analyzed, cells were grown in com-
pleted DMEM medium till 80-90% confluence, and then treated with 20µM of
βNF for 24h as described by Krusekopf (81). The viability of the cells was not
compromised, showing 91% and 86% (Table 4.2, no statistical significance) by
trypan blue and MTT, respect to control. The mRNA levels of the CYP1A1,
CYP1A2, CYP2A6 and UGT1A1 were measured by qRT-PCR in HepG2 cells
treated compared to control (Fig. 4.3).
A significant upregulation of 45.5fold (p≤0.01) of CYP1A1 was observed.
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viability assays
Treatment Trypan blue MTT
20µM βNF 24h 91% 86%
Table 4.2: Viability percentage of HepG2.
Cells were treated with 20µM of βNF viability was analyzed by trypan blue and MTT. Data are mean of 4-5
independent experiments.
Figure 4.3: mRNA expression in HepG2 treated with βNF.
CYP1A1, CYP1A2 and UGT1A1 expression analyzed by qRT-PCR. The obtained values were normalized
versus the expression of the endogenous house keeping genes GAPDH and HPRT. Control cells were treated
only with the vehicle (DMSO). Data are mean S.D. of 4 experiments. Significantly different when compared
to control (*p≤0.05,** p≤0.01). CYP2A6 was not expressed in this cell line.
Moreover, a 2.8fold upregulation of the CYP1A2 mRNA expression was detected.
The UGT1A1 mRNA expression was increased by 4.7fold (p≤0.05) compared to
control. Again, CYP2A6 was not expressed in our HepG2 cells (three different
primer pairs were used, one detailed by Abu Bakar (2).
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4.1.3 EROD/MROD activity
The CYP1A1 and CYP1A2 activity (refered as protein) was analyzed by the
two specific test assessing the dealkylation activity, EROD and MROD assay,
respectively. To set up the conditions for the assays, different concentration of
the substrates 7-ethoxyresorufin and 7-methoxyresorufin (EROD and MROD,
respectively, 1µM - 10µM) were tested over the time (90min). The optimal con-
centration chosen was 5µM for both compounds.
Huh7 revealed low EROD activity, the Cyp1a1 maximal possibility due to the
low induction (only 3fold of mRNA) allowed by viability restriction (20µM; 24h).
For HepG2 cells a significant increase in either assays was observed. EROD
activity (CYP1A1) resulted in 12fold higher respect to control (p≤0.01) and
MROD assay (CYP1A2), 4fold increased compared to control (p≤0.01) (Fig.
4.4). Due to its absence, CYP2A6 activity was not recorded.
Figure 4.4: EROD and MROD activity assays in treated HepG2.
Data are mean SD of 4-5 independent experiments. Significantly different from corresponding control
(**p≤0.01).
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4.2 Astrocyte primary culture
4.2.1 GFAP staining
To control the purity of the astrocytes cultures GFAP staining was performed.
After 12-15 days of cultures, cells were stained by GFAP antibody and Hoechst
for nuclei. The purity of astrocytes, identified by counting multiple fields, was
90-95% (Fig. 4.5).
4.2.2 Cyps constitutive expression
In order to evaluate the differences in constitutive levels of Cyps in Cx and Cll
astrocytes primary culture, the mRNA expression of Cyp1A1, Cyp1A2, Cyp2A3
and Ugt1A1 was assessed by qRT-PCR.
Fig 4.6 showed that only Cyp1A1 was 3fold higher (p≤0.05) in Cx astro-
cytes compared to Cll astrocytes. For the other genes there was a slight higher
expression but not statistically relevant in Cx astrocytes.
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(a) Representative immunostained of Cx rat astrocytes
(b) Representative immunostained of Cll rat astrocytes
Figure 4.5: Representative immunostaining of rat Astrocytes.
Green for astroglial GFAP (glial fibrillary acidic protein), and blue for nuclei. In this picture, primary Cx (a)
and Cll (b) astrocytes cultured for 10 - 12 days in vitro respectively (10 - 12 DIV) were grown on a glass
coverslip, fixed, and mounted on a glass microscope slide.
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Figure 4.6: Constitutive mRNA expression of Cyps astrocytes from Cx and Cll.
Cyp1A1, Cyp1A2, Cyp2A3 and Ugt1A1 mRNA expression. Values were normalized versus the expression of
the endogenous house keeping genes Hprt, Gapdh, Actin. Relative expression levels were calculated with
respect the normalized expression of the cerebellum at which it was assigned a value of 1. Data are mean S.D.
of 4-5 experiments. Significantly different when compared to control (*p≤0.05).
4.3 Inducibility of Cyps enzymes in Cx and Cll
astrocytes by βNF
4.3.1 Astrocytes βNF treatment
Several in vivo studies have used βNF as general inducer of Cyps (61, 95) but
their specific role in bilirubin oxidation in glial cells was not assessed.
Cx and Cll astorcytes cells were treated at different concentrations (2.5, 5, 10
and 20µM of βNF) and for different timing (1, 6 and 24h) in order to analyze the
inducibility of Cyps and select the optimal condition to assess the specific activity
(EROD/MROD) and most importantly, their capacity to oxidize bilirubin.
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4.3.2 Viability assays
Viability was assessed after the treatments using Tripan blue and MTT test.
The same trend was observed in both primary cultures. The first method dis-
played that all the treatments were not harmful for the cells (viability between
90-100% compared to control cells). MTT revealed that after 1h of treatment the
viability was similar to Trypan Blue (90-100%) whereas after 6 and 24h, as we
increased the drug concentration, the viability decreased in a dependent manner,
reaching a critical condition at the higher concentration (20µM of βNF) after
24h. This condition was excluded for the activity test (viability less than 50%,
p≤0.001) (Fig 4.7).
4.3.3 Cyps mRNA inducibility
Cyps inducibility was assessed at the βNF concentrations and timing de-
scribed above. Cyp1A1, Cyp1A2, Cyp2A3 and Ugt1A1 mRNA induction was
analyzed by qRT-PCR (Fig. 4.8 and 4.9).
4.3.3.1 Cortex derived astrocytes
In Cx astrocytes, Cyp1A1 mRNA expression was slightly modified after 1h
hour of treatment. After 6h of βNF treatement, regardless of the principle con-
centration, it was significantly higher (7.5fold, p≤0.05). After 24h, the level still
continued to be significantly higher till the maximal concentration, 20µM of βNF,
in which the expression decreased markedly to initial values (3.5fold). Maybe,
due to the decrease in viability (critical value).
The Cyp1A2 mRNA expression, after 1 and 6h was quite similar to control
cells and was significantly induced only after 24h (p≤0.05), increasing in a de-
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Figure 4.7: Viability of Cx and Cll astrocytes treated with βNF.
Viability is expressed as percentage in astrocytes treated with different concentrations of βNF (2.5, 5, 10,
20µM) analyzed at different timing (1, 6, 24h). Significantly different when compared to control
(*p≤0.05,**p≤0.01, ***p≤0.001).
pendent manner with the concentration of the drug. The maximal induction was
observed at the condition that we were forced to exclude due to the toxicity of
the treatment (20µM βNF; 24h, MTT: 30% viability; p≤0.001). On the other
hand, Cyp2A3 was significantly upregulated only after 24h at the higher con-
centration (12fold; p≤0.001) where the viability was compromised (MTT: 30%
viability; p≤0.001).
52
4.3 Inducibility of Cyps enzymes in Cx and Cll astrocytes by βNF
Figure 4.8: mRNA inducibility in Cx astrocytes treated with βNF.
Cyp1A1, Cyp1A2 and Cyp2A3 mRNA expression of treated Cx astrocytes with βNF at different
concentrations and timing (2.5, 5, 10, 20µM and 1, 6, 24h, respectively). Control cells were treated with the
vehicle (DMSO). Data are mean SD of 4-5 independent experiments. Statistical analysis is detailed in Table
4.3
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Cortex
Cyp1A1 µM βNF
Hours 2.5 5 10 20
1 p≤0.05 ns ns ns
6 p≤0.001 p≤0.05 p≤0.05 p≤0.05
24 p≤0.05 p≤0.05 p≤0.05 p≤0.01
Cyp1A2 µM βNF
Hours 2.5 5 10 20
1 p≤0.05 ns ns ns
6 ns p≤0.05 ns p≤0.05
24 p≤0.05 p≤0,01 p≤0.05 p≤0.05
Cyp2A3 µM βNF
Hours 2.5 5 10 20
1 ns ns ns ns
6 ns ns p≤0.05 ns
24 ns ns ns p≤0.001
Table 4.3: Stadistic analysis of Cx astrocytes mRNA
4.3.3.2 Cerebellum derived astrocytes
In Cll astrocytes, the Cyp1A1 mRNA induction was moderately increased
after 1 and 6h of βNF exposure, reaching the maximal upregulation of 5fold
(p≤0.05). After 24h of βNF treatment the expression increased even more,
achieving the highest value with 10µM (13fold; p≤0.05) and then, as in Cx as-
trocytes, decreased to initial ones (3fold). Of notice, again this condition corre-
sponded with the most toxic one for astrocytes (MTT 40% viability; p≤0.001) and
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for this reason was not used in the following experiments. Cyp1A2 and Cyp2A3
in cerebellum astrocytes were not clearly induced at any βNF concentration and
timing.
Ugt1A1 mRNA expression was also analyzed in both primary culture but in
neither was induced at any condition.
4.3.4 Optimal condition for selective Cyps enzyme activ-
ity analysis
The optimal conditions of Cyps induction were considered those (βNF con-
centration and timing) that allow the maximal upregulation of each specific Cyps,
together with the minimal/null modulation of the others Cyps (maximal selec-
tive induction). It was taken into account both the mRNA expression and the
viability (Table 4.5).
4.3.5 EROD and MROD activity
Once selected the optimal conditions, we performed the activity tests. In each
optimal condition, the EROD (Cyp1A1; refered as protein) and MROD (Cyp1A2;
refered as protein) tests were assessed in order to corroborate the mRNA modu-
lation with the functional induction.
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Figure 4.9: mRNA inducibility in Cll astrocytes treated with βNF.
Cyp1A1, Cyp1A2 and Cyp2A3 mRNA expression of treated Cll atrocytes with NF different concentrations
and timing (2.5, 5, 10, 20µM and 1, 6, 24h, respectively). Control cells were treated with the vehicle (DMSO).
Data are mean SD of 4-5 independent experiments. Statistical analysis is detailed in Table 4.4.
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Cerebellum
Cyp1A1 µM βNF
Hours 2.5 5 10 20
1 ns ns ns ns
6 p≤0.05 p≤0.05 ns p≤0.01
24 p≤0.05 p≤0.05 p≤0.01 p≤0.05
Cyp1A2 µM βNF
Hours 2.5 5 10 20
1 ns ns ns ns
6 ns p≤0.05 ns p≤¡0.05
24 p≤0.05 ns ns ns
Cyp2A3 µM βNF
Hours 2.5 5 10 20
1 p≤0.05 ns ns ns
6 ns p≤0,01 ns ns
24 ns ns ns ns
Table 4.4: Stadistic analysis of Cll astrocytes mRNA
4.3.5.1 Cortex derived astrocytes
The assays showed that in Cx astrocytes, when Cyp1A1 was selectively in-
duced the EROD test was 4fold increased (p≤0.01). In the same condition, the
MROD test was slightly but significantly increased (1.4fold, p≤0.05) (Fig. 4.10).
Under the Cyp1A2 optimal condition the activity tests revealed that both as-
says were significantly augmented, showing 4fold (p≤0.01) for EROD and 5fold
(p≤0.05) for MROD test (Fig. 4.11).
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4.3.5.2 Cerebellum derived astrocytes
In Cll astrocyte culture, under Cyp1A1 optimal condition, EROD assay was
principally induced having 2.5fold of increment (p≤0.01), with a concomitant
MROD activity increase of about 1.5fold (p≤0.05) (Fig. 4.10). Under the opti-
mal condition for Cyp1a2 (2fold mRNA, table 4.5) there was no upregulation in
neither of the activities test (Fig. 4.11).
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Figure 4.10: EROD and MROD activity in cells under the optimal condition for Cyp1A1.
Data are mean SD of 4-5 independent experiments. Significantly different when compared to control
(*p≤0.05,**p≤0.01).
60
4.3 Inducibility of Cyps enzymes in Cx and Cll astrocytes by βNF
Figure 4.11: EROD and MROD activity in cells under the optimal condition for Cyp1A2.
Data are mean SD of 4-5 independent experiments. Significantly different when compared to control
(*p≤0.05,**p≤0.01).
4.3.6 Specificity of EROD/MROD activity
Moreover, to analyze the contribution of each Cyp to the activity tests, a
Cyps inhibitor (fluvoxamine) was used. Fluvoxamine inhibits only Cyp1A2 at
lower concentrations (0.25µM) while at higher both Cyps are inhibited (100µM).
The same functional assays were performed as detailed above with the addi-
tion of fluvoxamine at low concentration (0.25µM) to inhibit selectively Cyp1A2.
What we expected to observe was normal EROD activity (Cyp1A1) and inhibited
MROD (Cyp1a2) test.
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For this reason we decide to analyzed Cx astrocytes treated for Cyp1A2 condi-
tion, where both mRNA and activity test were upregulated. The assay consisted
in perform the activity tests with or without the presence of the inhibitor. The
inhibition with fluvoxamine showed that only the MROD test was inhibited (no
signal) whereas EROD test was similar to the samples without inhibitor corrob-
orating the specificity of the tests (not shown).
4.4 Bilirubin Oxidation
4.4.1 Bilirubin Oxidation in βNF induced astrocytes
After selective induction of Cyps in Cx and Cll astrocytes we proceed to
extract the membrane fraction and evaluate the capacity of these Cyps to oxidize
bilirubin. 40µg of protein were incubated in presence of 15µM of bilirubin. The
test was initiated by the addition of NADPH (137µM) (Table 4.6). Again, the
liver model (HepG2 cell line) was used as control due to its expected maximal
activity.
The results showed, as expected, a higher constitutive capacity to oxidize
bilirubin in liver cells than astrocytes treated with βNF. After the treatment
a double of activity in HepG2 cells was observed. By HPLC analysis, some
glucuronidation products were detected due to Ugt1A1 activity (mRNA 4fold
upregualted). For astrocytes no glucuronidation products were observed.
4.4.1.1 Cortex derived astrocytes membrane fraction
In Cx astrocytes under Cyp1A1 treatment was observed a slight, but not sta-
tistically significant increase in bilirubin oxidation. However, under the Cyp1A2
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optimal condition we reported a significant increment in the bilirubin oxidation
compared to control (132%; p≤0.05).
4.4.1.2 Cerebellum derived astrocytes membrane fraction
In Cll derived astrocytes there were no mayor differences in bilirubin oxidation
under Cyp1A1 optimal condition. When it was assessed bilirubin clearance at
the condition for Cyp1A2 specific induction, even a slight decrease was observed
compared to control.
4.4.2 Bilirubin Oxidation by βNF induced astrocytes with
TCB
In liver, it has been studied that when Cyp1A1 was incubated with planar
polyhalogenated biphenyl substrates (such TCB), the capacity to oxidize bilirubin
was increased (28, 145). In order to evaluate if Cyp1A1 in brain astrocytes
behaves in the same manner, membrane fraction were challenged with BR and
TCB (3.42µM) (30). The reaction started with the addition of NADPH (same
protocol as described above) (Table 4.6).
We observed that the addition of TCB produced a high increment in bilirubin
oxidation initial rate. For Cx astrocytes under optimal condition for Cyp1A1,
a marked increase was observed (137% samples with TCB compared to control
with TCB; p≤0.05), demonstrating that TCB activates its capacity to oxidize
bilirubin. Moreover, in astrocytes under optimal condition for Cyp1A2 (both
Cyp1A1 and Cyp1A2 mRNA and activity were induced) the same increment was
observed as Cyp1A1 condition (140% samples with TCB compared to control
with TCB; p≤0.05).
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For Cll samples under the optimal condition for Cyp1A1, when TCB was
added a marked increase was observed (212% samples with TCB compared to
control with TCB; p≤0.05). Under the optimal condition for Cyp1A2, TCB
addition produced an increment in the rate of bilirubin oxidation (228% samples
with TCB compared to control with TCB; p≤0.05). In this latter condition
Cyp1A1 was also increased 4 folds in mRNA expression. (Controls means cells
induced with βNF but without TCB).
4.5 Viability challenge
4.5.1 Treatments with βNF (with or without TCB) and
bilirubin
The last step was to evaluate if the Cyps modulation (mRNA and activity)
that we detailed until now, was translated in an increased protection of astrocytes
towards bilribuin toxicity. In order to asses Cyps protection, MTT test was
performed in cells firstly induced by βNF and then exposed to bilirubin. Based
on the laboratory background, cells have been challenged with 140nM of bilirubin
for 24h leads to a viability compromising of about 40-50%.
4.5.1.1 Cortex derived astrocytes
The selective treatment for Cyp1A1 induction (βNF) in Cx, leaded to a 10%
decrease in viability (39%; p≤0.001), reversed by TCB addition (58%; p≤0.001).
On the other hand, when Cyp1A2 was induced in Cx astrocytes the viability
was significantly increased vs. uninduced cells (44%; p≤0.05). Unfortunately, the
64
4.5 Viability challenge
complete protection was not reached. The addition of TCB, further improved the
viability (56%, p≤0.05) (Fig.4.12).
Figure 4.12: Bilirubin viability challenge in cortex
Treated astrocytes with βNF (with or without TCB) were loaded with 140nM of bilirubin. Data are mean SD
of 4-5 independent experiments. Significantly different when compared to control with bilirubin
(*p≤0.05,**p≤0.001).
4.5.1.2 Cerebellum derived astrocytes
For cerebellum astrocytes, under the optimal condition for Cyp1A1, the vi-
ability without TCB was even lower than cells with no βNF treatment (50%;
not significant). When TCB was present the viability increased (62%, p≤0.05)
corroborating what observed in bilirubin oxidation experiment.
Under the optimal condition for Cyp1A2 induction, in which bilirubin oxida-
tion was slightly inhibited, the viability was reduced about 5% compared to cells
treated only with bilirubin (49%; p≤0.05). The same assay with TCB showed a
slight increment (not significant 58%) in viability compared to astrocytes with
bilirubin (Fig.4.13).
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Figure 4.13: Bilirubin viability challenge in cerebellum
Treated astrocytes with BNF (with or without TCB) were loaded with 140nM of bilirubin. Data are mean SD
of 4-5 independent experiments. Significantly different when compared to control with bilirubin (*p≤0.05).
4.6 Cyps inducibility and activity by UCB
To analyze if bilirubin itself was able to induce Cyps mRNA expression (44)
and activity and if the modulation was similar to βNF exposure, primary astro-
cytes cultures were treated with 25µM (Bf:140nM) of bilirubin for 2h.
4.6.1 Cyps mRNA expression
The mRNA analysis revealed that in both primary culture Cyp1A1 was signif-
icantly upregulated (5fold; p≤0.001 for Cx and 3.3fold; p≤0.01 for Cll). Cyp1A2
was also increase in both Cx and Cll derived astrocytes but only statistically rel-
evant in Cx (3.7fold; p≤0.05 vs. 2.5fold; no statistically significant, respectively).
Cyp2A3 expression was moderately increased in both primary culture but neither
significantly (Cx; 2fold; Cll: 1.5fold)(Fig. 4.14). Ugt1A1 mRNA was not induced
in neither cultures.
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Figure 4.14: mRNA relative expression of Cx and Cll astrocytes treated with UCB.
mRNA relative expression of Cyp1A1, Cyp1A2, Cyp2A3 in astrocytes from cortex (A) and cerebellum (B).
Values were normalized versus the expression of the house keeping genes Gapdh, Hprt, Actin. Relative
expression levels were calculated with respect the normalized expression of control samples (DMSO). Data are
mean S.D. of 4-5 independent experiments. Statistically relevant when compared to control (*p≤0.05,
**p≤0.01).
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4.6.2 Viability tests
Cell viability of treated astrocytes was unchanged after treatment by trypan
blue, while MTT showed a moderately decrease of 20-30% (Table 4.7).
4.6.3 EROD and MROD activity
Bilirubin treated astrocytes were harvested and membrane fraction was ex-
tracted as detailed in section 3.9. For the activity assays the membrane frac-
tions were resuspended in EROD/MROD buffer and incubated with the substrate
(ethoxyresorufin or methoxyresorufin, respectively) at 37◦C for 5 min. The reac-
tion was started by addition of NADPH (1µM final concentration). Fluorescence
was recorded over the time (90min).
The EROD and MROD activity in treated Cx astrocytes (Fig. 4.15A) showed
a significant increase (1.3fold and 2.8fold, respectively, both p≤0.05). The same
trend was observed by Cll astrocytes (fig.4.15B) in which both test were up-
regulated but only EROD test was significant (1.16fold p≤0.05 and 1.54fold,
respectively).
4.6.4 Additional controls under excluded conditions
Viability challenge assays were performed in the excluded condition as an ad-
ditional controls. As the maximal modulation of Cyp1A2 (mRNA) was reached
at the toxic concentration of βNF (20µM; 24h), we wondered to evaluate a possi-
ble benefit in term of viability vs. bilirubin challenge. It was performed the same
assays above described but with 20µM of βNF. The viability was less highly than
the control cells with bilirubin, confirming that at this condition the cells are
stressed as shown by MTT test and Cyps were unable to protect the cells despite
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Figure 4.15: EROD and MROD activity in Cx and Cll astrocytes treated with UCB.
EROD/MROD activity in Cx (A) and Cll (B) astrocytes loaded with 25µM for 2h. Data are mean SD of 4-5
independent experiments. Significantly different when compared to control (*p≤0.05).
the huge mRNA upregulation. This comforted us about the decision to exclude
the critical viability condition.
Moreover, in order to evaluate if bilirubin could predispose Cyps upregula-
tion to have an an additional increment in viability when incubated with βNF.
We performed a pretreatment with bilirubin of 140nM for 2h and then treated
with βNF. Unlikely, the results for bilirubin viability challenge were the same as
obtained without this preincubation (n=1).
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viability assays
Trypan Blue MTT
Cortex astrocytes 99% 70.2% (p≤0.001)
Cerebellum asotrocytes 99% 80% (p≤0.01)
Table 4.7: Viability percentage of astrocytes treated with UCB.
Cells from Cx and Cll loaded with UCB 140nM for 2h and viability tests were performed.
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4.7 Additional results
4.7.1 Protein analysis
To analyze the different behavior of Cyps among the regions Cyp1A1/Cyp1A2
were evaluated by SDS-PAGE Western blot analysis. As a positive control was
used rat liver. As Cyps isoforms shared more than 55% of the aminoacidity chain,
the selection of a specific antibody was difficult. For the Cyp1A2, the antibody
did no work well. Only recognized human liver samples (despite the company
stated that recognize rat) (not shown). Cyp1A1 protein was properly detected
and showed the same molecular weight as rat liver sample in Cx and Cll samples
4.16.
Figure 4.16: Western blot analysis of Cyp1A1
Positive control Rat liver microsomes (line 1). Cerebellum (line 2,3) and Cortex (line 4,5) membrane fraction
from astrocytes in line 2;3 and 4;5, respectively.
4.7.2 Signaling
To understand the different possible mechanisms of Cyps activation by βNF
vs. bilirubin, and between the two astrocytes preparations (cortex and cerebel-
lum), we performed further analysis by RT-PCR. Cyps regulation was mainly
reported due to Nrf2 and Ahr pathway (53, 78), so we analyzed them.
The analysis was performed in βNF treated cells after 6 and 24h and biliru-
bin treated astrocytes. Samples of 1h treated by βNF were not analyzed as we
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did not observe any clear upregulation of the Cyps. Again firstly we analyzed
the constitutive difference between Cx and Cll. Cx astrocytes revealed 2 fold
higher Nrf2 mRNA expression than Cll (p≤0.05), for the Ahr no differences were
observed (Fig.4.17).
Figure 4.17: Ahr and Nrf2 mRNA constitutive expression in Cx and Cll astrocytes
Values were normalized versus the expression of the house keeping genes Gapdh, Hprt. Cerebellar samples were
considered as 1. Data are mean S.D. of 4-5 independent experiments. Statistically relevant when compared to
contro (*p≤0.05).
The Ahr mRNA in Cx astrocytes was upregulated only after 24h at 10 and
20µM. For Cll astrocytes it was induced at the higher concentration of βNF
(20µM) at 6 and 24h, in a higher extent compared to Cx (Fig. 4.18). At 6h
in both cultures the Nrf2 expression increased slightly with the concentration of
the drug. After 24h of treatment the increment was more markedly, reaching the
maximum value at the higher concentration (20µM; critical viability). Again in
Cll cells the extent was higher compared to Cx cells (Fig.4.19).
For bilirubin treated astrocytes, from both regions the Ahr was downregulated
(p≤0.01 in Cx). On the other hand, the Nrf2 behaved differently between Cx and
Cll astrocytes. For Cx astrocytes a significant decrease was observed (p≤0.01)
while in Cll astrocytes was increased 1.5fold (p≤0.01) (Fig. 4.20).
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Figure 4.18: Ahr mRNA relative expression in Cx and Cll astrocytes treated with βNF.
Values were normalized versus the expression of the house keeping genesGapdh, Hprt. Relative expression
levels were calculated with respect the normalized expression of control samples (DMSO). Data are mean S.D.
of 4-5 independent experiments. Statistically relevant when compared to control.
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Figure 4.19: Nrf2 mRNA relative expression in Cx and Cll astrocytes treated with βNF.
Values were normalized versus the expression of the house keeping genesGapdh, Hprt. Relative expression
levels were calculated with respect the normalized expression of control samples (DMSO). Data are mean S.D.
of 4-5 independent experiments. Statistically relevant when compared to control (*p≤0.05, **p≤0.01).
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Figure 4.20: Ahr and Nrf2 mRNA relative expression in astrocytes treated with UCB.
Values were normalized versus the expression of the house keeping genes Gapdh, Hprt. Relative expression
levels were calculated with respect the normalized expression of each control samples (DMSO). Data are mean
S.D. of 4-5 independent experiments. Statistically relevant when compared to control (**p≤0.01).
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Cyotochrome P450 enzymes are the main enzymes involved in the detoxifica-
tion of drug and endogenous compounds. In liver, their role in bilirubin oxidation
has been deeply demonstrated (2, 3, 27, 145). From those studies, human and rat
Cyp1A1 and Cyp1A2 seem the most important enzymes in bilirubin detoxifica-
tion when conjugations is inhibited or reduced. A similar role has been discovered
for Cyp2A5 (corresponding to Cyp2A3 in rat, CYP2A6 in human) in mice. In ad-
dition, by the use of the Gunn rat, a model for Crigler-Najjar Type I syndrome, it
was shown that jaundiced newborn animals displayed an upregulation of Cyp1A1
and Cyp1A2 in liver compared with their not jaundiced littermates (70). Further-
more, their mRNA expression in brain was selectively induced (cortex, resistant
to UCB toxicity, higher and early vs. cerebellum, macroscopically damaged, hy-
poplasia, lower and delayed induction) by sulphadimethoxine injection (bilirubin
displacing agent) (44).
Despite that many works analyzed brain Cyps expression and induction, their
role in bilirubin oxidation has never been evaluated till now. The only demon-
stration of a bilirubin oxidative activity in the CNS became from the findings of
Hansen. His works supported the concept of bilirubin oxidation in brain by an
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unidentified enzyme called “bilirubin oxidase”. Despite sometime supposed be-
longing to Cyps family; the “bilirubin oxidase” had some characteristic that was
not quite in concordance with the cytochrome P450 enzymes (55, 56). Waiting
for identification of “bilirubin oxidase”, we focused our work on Cyps.
Although it was shown the presence of Cyp1A1 and Cyp1A2 in rats brain,
their distribution is contradictory (49, 61, 73, 83, 95). Between cell types it has
been shown that neuronal cells have higher constitutive expression than glial cells.
However, the inducibility is higher in the latter ones (73). For these reason we
chose to work with astrocytes primary cultures.
By the experiments performed in this thesis, we demonstrated that in both
Cx and Cll astrocytes treated by βNF, the principal Cyp to be induced was the
Cyp1A1, the Cyp1A2 was up-regulated only in cortex preparation, and Cyp2A3
was not possible to modulate without affecting the cellular viability (assessed by
MTT). Under optimal condition for the selective induction of each Cyp in cortex
derived cultures, a significant and specific (demonstrated by fluvoxamine exper-
iments) increase in the activity tests (EROD for Cyp1A1, MROD for Cyp1A2)
was detected, confirming the good correlation between mRNA and activity al-
ready suggested by Kapoor (73). This was not evident in cerebellum astrocytes,
maybe due to the low mRNA up-regulation reached by the treatment (Cyp1A1/
Cyp1A2 : 4fold and 2fold in Cll, vs. 7fold and 8fold in Cx), possibly not sufficient
to have a relevant protein modulation. These in vitro results are in agreement
with data obtained in living animals exposed to βNF. Iba works (61) described a
Cyp1A1 and Cyp1A2 constitutive expression (protein and activity) in both cere-
bellum and cortex with different induction pattern by βNF. Both regions resulted
in a significant increase in Cyp1A1 activity, but with a higher extent in cortex.
In concordance to our results, an incresed activity of the Cyp1A2 was observed
only in cortex. It is important also to point out that our result of EROD and
MROD increment were higher (Cx: 4 and 5fold; Cll: 2.5 and 1fold, respectively
vs. Iba et al. Cx: 1.9 and 3.7fold; Cll: 1.5 and 0.4fold, respectively). These dif-
ferences could be due to the treatment and samples used, in vivo vs. in vitro and
tissue microsomes of treated rats vs. astrocytes treated membrane fraction. Liu
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(83) used 3-MC as inducer and analyzed Cyp1A induction, showing a significant
increase in EROD test after 3 days of treatment and ROS generation. Unlikely,
the whole brain homogenates were used in this study.
Of interest, despite both cellular preparations were quite pure astrocytes cul-
tures, as characterized by GFAP staining (Fig. 4.5), we immediately observed
differences in the Cyps behavior. The Cyp1A1, Cyp1A2 and Cyp2A3 constitu-
tive level were slightly higher in Cx astrocytes compared to Cll cells, reaching
3 fold (p≤0.05) for Cyp1A1 (Fig.4.6). Furthermore, the induction of Cyps by
βNF was different in timing and extent in the different regions. Cyp1A1 induc-
tion in Cx astrocytes was an early event (6h) while in Cll the higher induction
was reached only after 24h. Moreover, Cyp1A2 was induced in Cortex after 24h
while in Cll was not clearly induced. Cyp2A3 in Cx was upregulated only at the
critical condition of viability, whereas in Cll was not upregulated (Fig. 4.8, 4.9).
Of notice, the strong difference in the Cyp1a1, 1a2 and 2a3 modulation by βNF,
among them and between the two “regions” may be explained in several ways.
First, we hypothesized the presence of different isoforms of Cyps between Cx and
Cll astrocytes, and between brain and liver. The Western blot results, seemed
to indicate that this was not the answer as no differences in molecular weight
(nor among brain areas, nor among brain and liver) were detected, at least for
Cyp1A1. Second, despite the brain is commonly considered “an organ”; it is,
in fact, a heterogeneous assembling of different regions, each of them possessing
different cellular populations. Among them, astrocytes also comprise different
types of cells (43, 87), making possible that the two preparations were represen-
tative of different “kind of astrocytes”. Third, the differential behavior that we
described (Cx vs. Cll derived astrocytes) may be due to a different maturational
stage of the two region (and contained cells) at the moment of the tissue dissec-
tion (P2 rats). It is well known that in rodents the cerebellum possess a delayed
development respect to the cortex (8, 117).
When we evaluated the bilirubin oxidation in astrocytes under the optimal
conditions to selectively induce each Cyp, a significant increase in the rate of
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bilirubin oxidation was recorded only after Cyp1A2 specific induction in Cx as-
trocytes, without any effect on bilirubin clearance under Cyp1A1 specific up-
regulation (Table 4.6). This leaded to consider that a delakylation reactions
(EROD/MROD) by cyotochrome P450 enzymes did not reflect the capacity of
Cyps to oxidize bilirubin. Thus, a proper analysis of the efficacy in protecting
toward bilirubin toxicity cannot be assessed with EROD/MROD assays, must
include a direct bilirubin clearance test. Moreover, we corroborated that Cyp1A2
seemed to be the principal brain Cyp involved in bilirubin oxidation in “phys-
iological conditions”, in agreement with previous finding in hepatocyte models
(107) and in mice (145).
In addition to the cited works (performed quite exclusively in liver models),
the dual role (monooxygenation and uncoupled activity) of Cyps is explained by
other studies (26). Usually Cyp1A2 is principally involved in bilirubin oxida-
tion in “physiological conditions”, due to its partially uncoupled state. Under
the same conditions, Cyp1A1 possess only limited enzymatic ability to degrade
bilirubin. Polyhalogenated biphenyl compounds (such as TCB in an appropri-
ate configuration), interact with the enzyme active site of Cyp1A1, uncoupling
the enzyme and producing the reactive oxygen species (ROS), which may oxidize
the bilirubin. Similarly, in our cultures when TCB was added in astrocytes and
Cyp1A1 induced, the enzyme became more able to oxidize bilirubin (both Cx
and Cll culture, p≤0.05). An interesting point was that in optimal condition for
Cyp1A2, in which both Cyps were induced (mRNA and activity), no synergic ef-
fect was observed. This is perfectly in agreement with the findings of Pons in liver
Cyps supersome and in mice by Zaccaro showing that TCB only favor Cyp1A1
bilirubin oxidation and diminish at the same time Cyp1A2 activity (107, 145).
Because bilirubin degradation may play both across the direct Cyps enzy-
matic activity and the degradation by Cyps uncoupling (ROS species) and the
latter alternative could be dangerous to the cell, we needed, the most important
information: the viability after induction ± uncoupling. The MTT assay demon-
strated that under the optimal condition for Cyp1A1 selective induction in Cx
and Cll (whitout TCB), the viability was even slightly reduced when compared
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to cells loaded with bilirubin alone. These results were in line with the absence
of changes in bilirubin oxidation assay. On the contrary, when TCB was present,
a significant increase in viability was assessed in both cultures (p≤0.05). After
Cyp1A2 induction (without TCB) a slight but significant increase in MTT was
shown in cortex, again in concordance with the capacity to oxidize bilirubin. The
addition of TCB incremented even more the viability. So, an improvement of
viability was finally reached in Cll, when Cyp1A1 was induced and uncoupled
by TCB, in concordance with the bilirubin oxidation assay (Fig. 4.12, 4.13).
This allowed us to confirm that, in the experimental condition that we tested,
the uncoupling of Cyps improve the viability by reducing the bilirubin toxicity
to the cell. Of notice, the HPLC analysis of products of bilirubin degradation
by Cyps, revealed that brain Cyps clearance became by oxidation (no glucoro-
nidation product detected), while in the liver model (HepG2) partial bilirubin
disappearance may be due to glucoronidation (products detected in the media).
This study started from an in vivo background, suggesting a role for brain
Cyps in CNS defense toward bilirubin, that we supposed due to their huge rise
in tissue. To conclude this work, we assessed brain Cyp modulation by bilirubin
itself. We obtained a similar trend of mRNA Cyps induction for all them (1A1,
1A2 and 2A3 ) in astrocytes of both regions (Cx and Cll), but in higher extent
in cortex (p≤0.001, p≤0.01), in agreement with Gazzin (44).
Again we faced a different (in this case in extent) modulation between brain
regions challenged with the same inducer. This may induce to consider the possi-
bility that the modulation of a target gene in a specific brain region may depend
from a heterogeneous presence of the signaling pathway (being different between
βNF vs. bilirubin and between the regions). Looking for bibliography, it was
difficult to find information about a regional pathways in different brain regions.
But if we consider that each brain region has different cell population, each with
their particular genes and protein expression, some differences are expected. Our
brief signaling study revealed that the constitutive expression of Nrf2 was sig-
nificantly higher in Cx compared to Cll, while no differences were detected for
the Ahr gene (Fig. 4.17). Moreover, in Cll astrocytes treated with bilirubin the
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Nrf2 was the only upregulated gene (p≤0.01) indicating some different regulation
between Cx and Cll (Fig. 4.20) supposing that UCB may skip Ahr receptor and
act “directly” on Nrf2. After βNF treatment, the Ahr was only induced at the
maximal concentration of βNF (20µM) after 6 and 24h in Cll and in Cx only at
the condition excluded by MTT test (20µM; 24h). As it is known that the βNF
works by Ahr receptor (118) and that transcription of downstream genes might
play only through the protein nuclear translocation and not through the mRNA
upregulation, protein analysis should be the ideal analysis. For the Nrf2 gene in
both astrocytes cultures we observed a drug dependant increase, markedly at the
critical condition (20µM; 24h) (Fig 4.18, 4.19). Of course this data should be con-
firmed by Nrf2 nuclear translocation as Nrf2 is modulated principally by protein
traslocation from cytoplasm to the nucleus and moreover ROS production.
In addition, our data might allow us speculate to a different subcellular lo-
calization between Cyp1A1 and Cyp1A2/2A3. In fact, when the maximal chal-
lenging with βNF, induce mitochondrial toxicity (showed by the MTT test) (Fig.
4.7), in this condition a markedly increase of Nrf2 mRNA expression, marker
of oxidative stress, was observed (Fig. 4.19). Furthermore, an specific decrease
of Cyp1A1 mRNA (on both Cx and Cll cultures) was observed. We could hy-
pothesize, that this Cyp could be located on the mitochondria. On the contrary,
under the same extreme challenging condition (and toxicity), Cyp1A2/2A3 were
upregulated (in cx astrocytes) (Fig. 4.8, 4.9). This might suggest a different sub-
cellular localization; less sensitive to mitochondrial alteration, such microsomes.
This hypothesis should be evaluated by collecting the subcellular fractions (nu-
clear, mithocondrial and microsomal) and assessing the presence of Cyps in each
fraction by Western blot analysis.
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• The Cyps mRNA inducibility by βNF was different in extent and timing
between Cx and Cll astrocytes. The Cx have an early response by Cyp1A1
(6h) and then by Cyp1A2 (24h), while Cll only late response of Cyp1A1
(24h). Cyp2A3 was only induced at the critical condition in Cx and not
induced in Cll.
• The difficulties in induction (mRNA and activity) cerebellar Cyps leave
unprotected the Cll (most damaged region in rodents by bilirubin (15, 45))
under “physiological conditions”.
• Cyp1A1 was induced in both primary cultures (mRNA and activity) but
produced no changes in bilirubin oxidation. The addition of TCB, uncou-
pled the Cyp1A1, increasing the bilirubin oxidation capacity and improving
the viability, importantly in cerebellar astrocytes.
• Cyp1A2 was induced by βNF only in cortex (mRNA and activity) and
bilirubin was oxidized by this enzyme without the need of TCB.
• Bilirubin was able to induce Cyps mRNA expression and activity, corrobo-
rating our hypothesis of a bilirubin role in vivo. In agreement, Cyp1A1 and
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Cyp1A2 induction from cortex was higher compared to Cll. Cyp2A3 was
not significantly induced by BR in vitro, despite a trend of upregulation.
• This study revealed that Cyp1a1 and Cyp1a2 in astrocytes are inducible
and able to oxidize bilirubin. Viability studies revealed that Cyps were
active to protect cells form bilirubin damage, particularly in cerebellum
(damaged region).
• Further studies should be performed to elucidate if the induction by βNF
and uncoupling agents could overcome the bilirubin damage in vivo, as a
possible treatment to bilirubin encephalopathy.
• βNF and bilirubin produced different Cyps induction behavior, suggesting
that might work by different pathways. This study should be continue by
evaluation of Nrf2 and Ahr nuclear translocation, to improve the possibility
to modulate cerebral Cyps, specially from cerebellum.
• Finally, as the Cyps maximal protection, by bilirubin oxidation, play across
uncoupling and ROS generation, ROS must be evaluated in the future ex-
periments.
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